AU754476B2 - Backbone-cyclized BPI peptidomimetics - Google Patents

Description

P/00/01 1 Regulation 3.2

AUSTRALIA

Patents Act 1990

ORIGINAL

COMPLETE SPECIFICATION STANDARD DIVISIONAL PATENT Invention Title: 'Backbone cyclised BPI peptidomimetics' The following statement is a full description of this invention, including the best method of performing it known to us: W O 9 7 0 9 3 4 4P C T L 9 6 0 0 0 9 1 BACKBONE CYCLISED BPI PEPTIDOMIMETIGS Field of the invention This i nveni-,-n relates to libraries of cofforationaliv constrained bacyo cyclized Peptioieistmthd fr the production Off such libraries and to methods Of using them to screen ffor -biolocically active Crpud.Wti h cop of ths Invention are certain novel confornationally, constrained peptidOmimetic molecules which are disclosed and claimed herein.

~Backg-round of th- Ieto Peptlde libraries Classically, the Pharmaceu~tical industry has scenda wide variety oa- compounds derived from fl~Btural sources to .yiel~d potential drug candidates or lead compounds ffor the development off new drugs. These laborious screening efforts have relied on the random testing of a vast number of .chemical entities. In recent year s, various strategies have been adopted f or the generation off libraries off compounds that-are subseguent~y screened as a novel, rational approach to drug discovery and development.

has become apparent that a variety ofmehdlgs can be applied to the problem of generating a diverse group of candidate compounds, based on the known principles off peptide chemistry and/Or molecular biology. Peptides are a convenient class of molecules for the generation of combinatorial libraries, since they are composed of a finite set off amino acid building units, which can be efficiently assembled either by chemical synthesis or transcription/translatio of DNA. Combinatorial libraries are discussed by Gallo5p et al., C e 37, 1233-1251 1- WO 97/09344 PCT/IL96/00091 (1994); Gordon et al., J. Med. Chem., 37, 1385-1401 (1994); Pinilla et al., Biopolvmers (Peptide Science), 37, 221-240, (1995); and Lebl et al., Biopolvmers (Peptide Science), 37, 177-198 (1995). The set of amino acid building units can include only the naturally encoded amino acids, when the libraries are encoded by oligonucleotides on a plasmid, phage, or any other vector. This set can be expanded to include both D and L amino acids and/or non-natural amino acids in synthetic libraries.

Linear peptides suffer from several serious drawbacks as potential drugs, inasmuch as they are notoriously unstable in vivo, often lack high affinity of binding to their receptor, frequently lack selectivity to one kind of receptor, and generally have poor oral bioavailability. In efforts to overcome such problems, it is also possible to utilize the methodologies developed in connection with synthetic peptide libraries to generate collections of cyclic peptides, novel biopolymers and even novel branched oligomeric compounds, reviewed by Zuckermann, Current Opinion in Structural 20 Bioloyv, 3, 580-584 (1993).

One of the most significant synthetic technologies that facilitate the generation and screening of diverse chemical libraries is the resin-splitting method, which is a polymer supported multiple synthesis procedure that allows a high 25 degree of control over the composition of a peptide mixture.

Mixtures are generated by dividing a solid support into individual portions, and coupling a different amino acid to each portion, and then recombining the portions. These steps may be performed in an iterative fashion to provide the required degree of diversity.

Totally random libraries-generated by these types of methods are disclosed in W092/00091 and W092/09300. Each individual bead will contain a unique peptide sequence, which can be probed for activity with a soluble receptor or antibody. Positive beads can be isolated and sequenced using Edman sequencing chemistry. W092/00091 further discloses methods to provide selectively cleavable linkers between 2

I,,

WO 97/09344 PCT/IL96/00091 peptide and resin, such that part of the peptide can be liberated from the resin and assayed for activity in soluble form, while another part can be sequenced. In addition, it is also possible to generate random libraries in which each bead carries more than one peptide, by coupling of mixtures of amino acids to the beads, as disclosed by Hornik et al., Reactive Polymers, 22, 213-220 (1994).

Another methodology is disclosed by Geysen et al., J.

Immunol. Meth., 102, 259-274 (1987), which involves the synthesis of peptides on derivatized polystyrene pins which are arranged in such a fashion that they correspond to the arrangement of wells in a 96-well microtiter plate.

Individual chemical reactions can be performed in each well, thereby yielding individual peptides on each pin. The pins 15 are typically probed using an enzyme linked immunoassay (ELISA) or radioimmunoassay (RIA), carried out in the microtiter wells, or the peptides may be released from the pins and tested in solution. The mimotope approach of Geysen t al. generates diverse peptides that are probed for o 20 activity in situ. The best dipeptide sequence is selected for elongation to diverse tripeptides, the best tripeptide is selected for elongation to a tetrapeptide and so on.

Ideally, chemistries that are amenable to combinatorial library synthesis would have the following characteristics: 25 be polymer-supported to facilitate the resin splitting technique; be assembled in high yield with automatable chemistry; and allow the incorporation of a wide variety of chemical functionalities.

Cyclic peptides Cyclic peptides are generally recognized as possessing enhanced bioavailability due to increased metabolic stability, as well as a relatively constrained conformation when compared to the same sequence in a linear form. The enhanced metabolic stability should allow diminished doses at longer intervals. The restricted conformation should improve the drug selectivity, thereby potentially preventing side- 3 Ik WO 97/09344 PCT/IL96/00091 effects. All of these properties are desirable in conjunction with the quest for new drug candidates.

The generation of libraries of cyclic peptides requires, in addition to any previously stated considerations, that the cyclization reaction be performed in a high yield and with a minimum of additional manipulations. Unfortunately, classical cyclization reactions are highly sequence dependent in terms of the expected yields, making the uniform cyclization of a peptide mixture unreliable.

Recent advances in the cyclization of peptides directly on the solid support have improved the synthetic procedure, and even allowed the automation of cyclization reactions based on known cyclization schemes. In the past, cyclizations were typically performed in solution under conditions of high 15 dilution. Polymer-supported cyclizations can both avoid potential side reactions such as oligomerization and facilitate product purification. For example, on-resin i cyclization methods have recently been used to prepare S I cyclopeptides with bridges formed of thioethers, disulfides, 20 or lactams between two side chains, lactams between the amino terminus and a side chain, and lactams between the amino and carboxy termini (reviewed by Zuckermann, Current Opinion in Structural Biology, 3, 580-584 (1993).

The use of resin-bound cyclic peptides and free cyclic 25 peptides in combinatorial libraries is disclosed in WO 92/00091. However, these cyclic peptides do not contain any conformationally constraining element, and in cases where cyclization is achieved, these peptides may still adopt a number of conformations and suffer many of the same shortcomings as linear peptides.

Cyclic semi-random peptide libraries, which are disclosed in WO 95/01800, are exclusively cyclic pentapeptide and hexa-peptide libraries containing one or more randomized amino acids and a conformationally constraining element in the form of an amino acid residue such as proline which fixes the beta turn angles of the adjacent amino acid residues. The advantages of such conformationally 4 WO 97/0934 PCT/LL96/00 091 Constraining elements is Stressed by the inventors of this approach. However, incllusion of such elements via incorporation of a particular amino acid residue into the peptide sequence may have detrimental effects on those residues required for receptor recognition or other biological activity. Furthermore, in WO 95/01800., the cycjlizatjon'reaction is merely another coupling reaction in which the terminal amino group of the linear peptide is coupled to the terminal carboxy group of the peptide.

Backbone cyclized peptides Backbone cyclized peptides are generally known, as discussed, for instance, in Gilon et al., Biopolmers31, 745-750 (1991); in EPO 564,739 A.2; and in WO 95/33765 (PCT/IB95/0045 5 Such compounds have not been used for c o n t r u t i n l i r a r e s f o r s c r e e n i n g p r o e V. In addition, methods are known for combining amino acids *.into peptides. U.S. Patent 5,010,175 describes another meho of incorporating random amino acids into a peptide.

:.According to that method, a mixture of amino aisi incorporated by coupling a mixture in which the individual amino acids are present in varying proportions depending upon their relative rates of reaction in the coupling, the amount of amino acid is inversely proportional to its rate of coupling.

too.

004117956 Summary of the invention In one aspect, the invention provides a backbone-cyclized peptide analog of a fragment of bacterial/permeability increasing protein 23(BP23)having anti-fungal activity, comprising a peptide sequence of BPIT wherein at least one pair of backbone nitrogens in the peptide sequence is linked together to form a backbone-cyclized peptide analog having anti-fungal activity and having the general formula Q-{AA}-N-CH(R)-CO- {AA r-E Fonula (I) wherein; d, e, and f each independently designates 0 or an integer from I to 10; each {AA} designates an amino acid residue or the residue of a plurality of amino acids linked together through peptide bonding, wherein each {AA} may be the same or different; Q represents H or an acyl group; E represents a hydroxyl group, a carboxyl protecting group or an amino group, or the carboxy terminal group CO-E, wherein the CO is part of {AA}, can be reduced to CHrOH or CHO; each of R and R' is independently hydrogen or an amino acid side-chain optionally bound with a specific protecting group; and the line designates a bridging group of the formula: or (ii) -X-M-Zwherein: M and W are independently selected from the group consisting of disulfide, amide, thioether, thioester, imine, ether, and alkene; and X, Y and Z are each independently selected from the group consisting of alkylene, substituted alkylene, arylene, hono- or hetero- cycloalkylene and substituted cycloalkylene.

In another aspect, the invention provides a backbone-cyclized pepetide analog of a fragment of bacterial/permeability increasing protein 23(BPIz3)having anti-faugal activity, comprising a peptide sequence of BPI.j wherein the backbone of the peptide analog is cyclized to a sidechain of an amino acid to form a backbone-cyclized peptide analog with anti-fungal activity and having the general Formula (II): 004117956 Q. {AA} rN-CH(R)-CO-t(AA},-NH-CCO- {AA} rE Formula (II) wherein; d, e, and f each independently designates 0 or an integer from 1 to 10; each {AA} designates an amino acid residue or the residue of a plurality of amino acids linked together through peptide bonding, wherein each {AA} may be the same or different; E represents a hydroxyl group, a carboxyl protecting or an amino group, or CO-E, wherein the CO is part of can be reduced to CHz-O0H; R is an amino acid side chain optionally bound with a specific protecting group; and the line designates a bridging group of the formula: or (ii) -X-M-Zwherein M and W are independently selected from the group consisting of disulfide, amide, thioether, imine, ether, and alkene; X, Y and Z are each independently selected from the group consisting of alkylene, substituted alkylene, arylene, cycloalkylene and substituted cycloalkylene.

In another aspect, the invention provides a backbone-cyclized peptide analog of a fragment of bacterial/permeability increasing protein 23(BPl23)having anti-fungal activity, comprising a peptide sequence of BP ls'wherein the backbone-cyclized peptide analog has anti-fungal activity and has the general formula (III): Q- AAjI-BUi-{AA} ,-BU {AA} -BU 3 {AA}b-BU- {AA} r- I J Formula (IIU) wherein: a and b each independently designates an integer from 1 to 8 or zero; d, e, and f each independently designates an integer from 1 to 10 or zero; {AA} designates an amino acid residue -HN-CH(R)-CO-wherein R is an amino acid side chain, optionally bound with a specific protecting group, and the amino acid residues in each chain may be the same or different; Q represents H or an acyl group; E represents a hydroxyl group, a I

N

carboxyl protecting group or an amino group, or the carboxy terminal group CO-E, wherein the CO is part of can be reduced to CIHarO or CHO; BU represents an functionalized derivative of amino acids of formula (IV):

X

Formula (IV) wherein X is a spacer group selected from the group consisting of alkylene, substituted alkylene, arylene, cycloalkylene and substituted cycloalkylene; R' is an amino acid side chain, optionally bound with a specific protecting group; and G is a functional group selected from the group consisting of amines, thiols, alcohols, carboxylic acids and esters, and alkyl halides; which is incorporated into the peptide sequence and subsequently selectively cyclized via the functional group G with one of the side chains of the amino acids is said peptide sequence or with another w-functionalized amino acid derivative; and the lines designate a bridging group of the formula: 15 or (ii) -X-M-Zwherein: one of the lines may be absent; M and W are independently selected from the group consisting of disulfide, amide, thioether, thioester, imine, ether, and alkene; and X, Y and Z are each independently selected from the group consisting of alkylene, substituted alkylene, arylene, homo-cycloalkylene, or hetero-cycloalkylene and 20 substituted cycloalkylene.

S' In another aspect, the invention provides a backbone-cyclized peptide analog of a fragment of bacterial/permeability increasing protein 23 (BP[l) having anti-fungal activity comprising the following BP3 peptide sequence: Lys-Trp-Leu-Ile-Gln-Leu-Phe-His-Lys-Lys wherein up to four amino acid residues of the BPI 2 3 peptide sequence are replaced with a building unit, a differnt amino acid residue or is absent and wherein the BPI?1 peptide sequence has at least one building unit with at least one backbone nitrogen in the peptide sequence linked to a side chain of at least one other amino acid in the peptide sequence or 004017956 to at least one other backbone nitrogen in the peptide sequence by a bridging group comprising a disulfide, amide, thioether, thioester, imine, ether, or alkene to form a backbone-cyclized peptide analog having anti-fungal activity.

In another aspect, the invention provides a backbone-cychized peptide analog of a fragment of bacterial/permeability increasing protein 23 comprising a peptide sequence having at least one building unit having an W-a derivative of an amino acid, wherein at least one backbone nitrogen in the peptide sequence is linked to a side chain of at least one other amino acid in the peptide sequence or to at least one other backbone nitrogen in the peptide sequence by a bridging group comprising a disulfide, amide, thio ether, thioester, iniine, ether, or alkene to form a backbone-cyclized peptide analog, wherein the peptide sequence has the formula: Q-Lys-AA--AA---AA4 Ms-AA6--AAr-Asg-AA9--iYS-E wherein: Q represents H or an acyl group; E represents a hydroxyl group, a carboxyl protecting group or an amino group, or the carboxy terminal group CO-E, wherein the CO is part of an amino acid residue, can be reduced to C}{ 2 -OtI or CHO-, AA 2 is Trp, 2NaI, ~~D2Nal,lINa!, DINaIGy-C 4 or Gly-M'- AA 3 is LenGIY-C* or Gly-N% "A 4 is absent, Rle,! la, Gy-C~or Gl.~N, AA5 Is Gin, Giy-C+ or Gly-N*; AA6~ is Len, Gly-C* or Gly-N*;

AA

7 is Phe, M~e, P~h- pNO2?he, pFPhe, Gly-C* or Gly-N*; AX 1 is His, Gly-C"' or Gly-N-0;

AA

9 is ~ys, Gly-C* or Gly-N*; and is mateger from Ito 3, wherein a bridging group extends frora OWOf AA 2

AA

3

AA

4 or AA 5 to one of A&AA 7 AA&, or AA to form a cyclic strcr.

In another aspect, the invention provides a method for the preparation. of a backbone-cyclized peptide analog of a fragment of bacteriallpermeability increasing protein 23 (B Pi3). having anti-fungal activity, comprising a peptide sequence of BPI2 3 having at least one building unit comprising an N 0 derivative of an amino acid, wherein at least one backbone nitrogen in the peptide sequence is linked to a side chain of at least one other amino acid in the peptide sequence or to at least one other backbone nitrogen in the peptide sequence. by a bridging group comprising a disulfide, amnide, thioether, 004117956 thioester, imine, ether, or alkene bridge to form a backbone-cyclized peptide analog; said method comprising the steps of: providing a BPh3peptide sequence; and incorporating into the peptide sequence at least oneN,--functionalized derivative of an amino acid of formula (IV):

-N-CH(R')-CO-

X

G

Formula (IV) wherein X is a spacer group selected from the group consisting of alkylene, substitued alkylene, arylene, cycloalkylene and substituted cycloalkylene; R' is an amino acid side chain, optionally bound with a specific protecting group and G is a functional group selected from the group consisting of amines, thiols, alcohols, carboxylic acids and esters, aldehydes, alcohols, and alkyl halides, by selectively cyclizing a functional group G with another w- functionalized amino acid derivative or with one of the side chains of the 15 amino acids in said peptide sequence to form the backbone-cyclized BPIa peptide analog.

The present invention provides a library of chemical compounds that comprises a plurality of backbone-cyclized peptide analogs. Each compound in the library contains a peptide sequence having at least one building unit comprising an N-derivative of an 20 amino acid, and at least one backbone S j A WO 97/09344 PCT[L%/0009.

nitrogen in each said peptide sequence is linked to a side chain of at least one other amino acid in the peptide sequence or to at least one other backbone nitrogen in the peptide sequence by a bridging group comprising a disulfide, amide, thioether, thioester, imine, ether, or alkene bridge to form a backbone-cyclized peptide analog. At least one of the building units is preferably located other than at the end of the peptide sequence, and more preferably, none of the building units is located at the end of the peptide sequence.

The newly generated libraries, disclosed according to the present invention, now enable screening for varying degrees of conformational constraint, in order to determine the optimal conformation of a peptide or peptide analog in performing its role as an agonist or antagonist. This is accomplished by generating a library of chemical compounds that comprises a plurality of backbone-cyclized peptide analogs, wherein the members of the library vary in: the positions in the linear seauence of residues that are to be cyclized, (ii) the length of the bridge between these 20 residues, (iii) direction of the bridge between these residues; and (iv) the bond type of the bridge between these residue. This novel type of library thereby enables the improvement of a known sequence of residues by screening for the optimal sequence of an active peptide analog.

25 In another one aspect of the invention, the library as described above comprises a plurality of backbone-cyclized peptide analogs, wherein at least one pair of backbone nitrogens in each peptide sequence is linked together to form a peptide analog having the general formula 30 1 Q-(AA) -N.CH(R)-CO-{AA) -N.CH(R' -E Formula (I) SUBSTITUTE SHEET (RULE 261 WO 97/09344 PCT/IL96/00091 wherein: d, e, and f each independently designates 0 or an integer from 1 to 10; each {AA} designates an amino acid residue or the residue of a plurality of amino acids linked together through peptide bonding, wherein each {AA} may be the same or different; Q represents H or an acyl group; E represents a hydroxyl group, a carboxyl protecting group or an amino group, or the carboxy terminal group CO-E, wherein the CO is part of can be reduced to CH 2 -OH or CHO; each of R and R' is independently hydrogen or an amino acid sidechain optionally bound with a specific protecting group; and the lines designate a bridging group of the formula: or (ii) -X-M-Zwherein: M and W are independently selected from the group consisting of disulfide, amide, thioether, thioester, imine, 1 5 ether, and alkene; and X, Y and Z are each independently selected from the group consisting of alkylene, substituted alkylene, arylene, homo- or hetero-cycloalkylene and substituted cycloalkylene.

In another aspect of the invention, the library comprises a plurality of backbone-cyclized peptide analogs, wherein the backbone of each analog is cyclized to a sidechain of an amino acid to form a peptide analog of the general formula

(II):

Q-(AA}d -N-CH(R).CO-(AA} -NH-CH-CO-(AA),

-E

Formula

(II)

wherein the variables are as disclosed above.

A further library in accordance with the present invention comprises a plurality of backbone-cyclized bicyclic peptide analogs, each of which comprises a plurality of building units comprising an NO-derivative of an amino acid.

Such bicyclic peptide analogs may have the formula

(III):

7 w~~e~~re~~fu each J arnt a ti1 zed erjvatve ofaz.inc- acids Of 'LcrMu.aa(V N-CHC

)O

IsI Fo'a-

V

2a wherein h ropcnisigo Xis a spacer a_01,P fromtb Cflifg .M -e aJypne ayyn1 =Yioikyeee n 5 titut-d cylalkylele; Y' is an &-mino acid side dHain =ptionally bound wit'-, a specifC i.P o etn group; and G s a 2S fUnCticflal group selected fo= the rrou.p consi~stig of am~ethils, a1Thols, cabOCYlic acid.s and esters, and alkyl- halides; and the other vari~ables are as disclosed abv.T*B rup -aicoprae notepptd e.s-Vence and miy sxibsecrOefly be se 8 t~Yccid.v.th 3a functionl group G~ Vith, one cf the side chains of the ami-no acids in said peptide seuel1c*e or Wit another wfflc-tinalized aminlo acid de.rivativese It Is preerre e, th~at 2ihraries in aOr da.nce with the present inventionf, such as those descriled above, have at leastVfo=r ters.

-8- In another preferred embodiment of the present invention, the library as described above comprises two or more sublibraries, each containing a plurality of related peptide analogs.

The present invention provides methods for screening for bioactive conformationally constrained peptide analogs. A method of screening for active conformers comprises: generating a library of chemical compounds that comprises a plurality of backbone-cyclized peptide analogs, wherein the members of the library vary in: the positions in the linear sequence of residues that are to be cyclized, (ii) the length of the bridge between these residues, (iii) direction of the bridge between these residues, and (iv) the bond type of the bridge between these residues; screening the library for bioactivity; and identifying the active member or members of the library.

The present invention also provides methods for the preparation of libraries of chemical compounds as described above. The methods comprise .the steps of: providing peptide 20 sequences having a plurality of building units containing amino acids and linked nitrogen atoms and incorporating into each peptide sequence at least one N°-w-functionalized derivative of an amino acid of formula (IV) by selectively cyclizing a functional group G with another w-functionalized 25 amino acid derivative or with one of the side chains of the amino acids in said peptide sequence to form backbonecyclized peptide analogs.

-Preferred embodiments for G in formula (IV) include amine, thiol, and carboxyl groups. Preferred embodiments for R and R' in formulas include CH3-, (CH3)2CH-, (CH3)2CHCH2-, CH3CH2CH(CH3)-, CH3S(CH2)2-, HOCH2-, CH3CH(OH)-, HSCH2-, NH2C(=0)CH2-, NH2C(=0)(CH2)2-, NH2(CH2)3-, HOC(=O)CH2-, HOC(=0)(CH2)2-, NH2(CH2)4-, C(NH2)2 NH(CH2)3-, HQ-phenyl-CH2-, benzyl, methylindole, and methvlimidazole.

A particularly useful embodiment of the present invention involves providing the peptide sequences as 9 WO 97/09344 PCT/IL96/00091 described above covalently coupled to insoluble polymeric supports.

The present invention also provides a method of screening the compounds contained in the libraries for biochemical and biological activity. This method comprises forming a library of cyclized peptide analogs as described hereinabove and screening for those peptides that exhibit a similar activity to the natural peptide, or, alternatively, inhibit the activity of the natural peptide. For example, and not by way of limitation, some peptide analogs may act as agonists of the corresponding natural peptide's receptor, whereas other peptide analogs may act as antagonists of the corresponding natural peptide's receptor. These methods are exemplified herein for bradykinin analogs, Substance

P

15 analogs, BPI analogs, somatostatin analogs, and interleukin-6 inhibitory peptide analogs.

Description of the Preferred Embodiments In order to fully describe the present invention, the following definitions will be used.

A "library" of backbone cyclized peptide analogs indicates a collection of peptide analogs wherein at least one conformational constraint consisting of a bridge linking novel building units via modified side chains attached to the 25 nitrogens of the amide bonds is present. Typically the amino acids in other positions of the peptide will be "variable" or "constant". Each library is characterized by its building units, its constant amino acid residues and its variable amino acid residues. Each library may be composed of "sublibraries" which are synthesized in parallel, using a divergent or convergent synthetic scheme.

A "variable" position or amino acid residue may have more than one amino acid in the specified position of the peptide. Typically, in a set of sub-libraries, each sublibrary differs from the other in the identity of at least one of its defined amino acid(s) the defined amino acid(s) will be constant throughout a single sub-library, yet 10 WO 97/09344 PCT/IL96/00091 differ between sub-libraries within the set). A "constant" amino acid or sequence is one whose identity and position are invariant throughout the peptides of the library, and across a set of sub-libraries.

The conformation of a peptide backbone is determined by the three dihedral angles 0 0 (N-Ca-C-N) and w (Ca-C-N-Ca), which not only specify the position of the peptide backbone atoms, but also the angle of projection of the amino acid side chains (Ca-Cb vector) from the peptide backbone. A peptide with a "conformationally constrained backbone" will either be rigid, existing in only a single conformer characterized by specific values of 4, and w for each residue, or will exist as an equilibrium mixture of a relatively few discrete conformers, the backbone torsional 15 angles of all residues for each conformer being well described. Thus, a backbone-cyclic peptide with a conformational constraint indicates one in which the atoms 'I and bonds which constitute the ring are energetically able to assume only a limited number of positions in space relative to one another at or around room temperature, and these positions may be well defined by conventional techniques of molecular modeling and crystallography.

An "optimized" conformer is that which has the greatest activity biological response, binding or inhibition of 25 biological response or binding) when a library having a defined amino acid sequence is screened for a given target activity. Preferably, only a single bridge will confer optimal activity. An optimized bridge is characterized by its chemical structure and position in the peptide sequence The "amino acid set" comprises all amino acids which are to be varied within the peptide at a particular position.

Typically the amino acid set will comprise 2-50 different amino acid residues. The amino acid set may be varied in the number of amino acid residues and types of residues for each position in the peptide, or the same set may by used for all positions in the peptide.

11 WO 97/09344 PCT/IL96/00091 The term "amino acid" refers to compounds which have an amino terminus and carboxy terminus, preferably in a 1,2or 1,4- substitution pattern on a carbon backbone.

a-Amino acids are most preferred, and include the 20 natural amino acids (which are L-amino acids except for glycine), which are found in proteins, the corresponding D-amino acids, the biosynthetically available amino acids which are not found in proteins 4-hydroxy-proline, 5 -hydroxy-lysine, citrulline, ornithine, canavanine, djenkolic acid, Pcyanolanine), and synthetically derived a-amino acids, such as amino-isobutyric acid, norleucine, norvaline, homocysteine and homoserine. 1-Alanine and 7-aminobutyric acid are examples of 1,3- and 1,4-amino acids, and many others are well known to the art. Statine-like isosteres (a dipeptide 15 comprising two amino acids wherein the CONH linkage is replaced by a CHOH), hydroxyethylene isosteres (a dipeptide comprising two amino acids wherein the CONH linkage is replaced by a CHOHCH,), reduced amide isosteres (a dipeptide comprising two amino acids wherein the CONH linkage is replaced by a CH 2 NH linkage) and thioamide isosteres (a dipeptide comprising two amino acids wherein the CONH linkage is replaced by a CSNH linkage) are also useful residues for this invention.

As used herein "peptide" indicates a sequence of amino 25 acids linked by peptide bonds. The peptide analogs of this invention comprise a sequence of amino acids of 4 to 12 amino acid residues, preferably 6 to 10 residues, each residue being characterized by having an amino and a carboxy terminus.

A "building unit" indicates an N-derivatized a-amino acid of the general Formula

IV:

12 WO 97/093 4 PCT/IL96/00091

-CH(R')-CO-

X

G

Formula (IV) wherein X is a spacer group selected from the group consisting of alkylene, substituted alkylene, arylene, cycloalkylene and substituted cycloalkylene; R' is an amino 15 acid side chain, optionally bound with a specific protecting Sgroup; and G is a functional group selected from the group consisting of amines, thiols, alcohols, carboxylic acids and esters, and alkyl halides; which is incorporated into the peptide sequence and subsequently selectively cyclized via 20 the functional group G with one of the side chains of the amino acids in said peptide sequence or with another wfunctionalized amino acid derivative.

The methodology for producing the building units is described in international patent application 00455, which is incorporated in its entirety by way of reference. The building units are abbreviated by the three letter code of the corresponding modified amino acid followed by the type of reactive group (N for amine, C for carboxyl), and an indication of the number of spacing methylene groups.

For example, Gly-C2 describes a modified Gly residue with a carboxyl reactive group and two methylene spacer, and Phe-N3 designates a modified phenylalanine group with a amino reactive group and three methylene spacer.

As used herein "linear peptide" denotes the peptide sequence that is constructed only of amino acid residues and is devoid of any building units.

-13- SUBSTrIrrF SHFT (RI fln WO 97/09344 PCT/L96/00091 As used herein "backbone cyclic peptide" denotes an analog of a linear peptide which contains at least one building unit that has been linked to form a bridge via the alpha nitrogen of the peptide backbone to another building unit, or to another amino acid in the sequence.

As used herein "pre-cyclic peptide" denotes an analog identical to the cyclic analog except that it is retained in the non-cyclized form to serve as control during the biological or other screening assays.

"Pre-cyclic peptide library" denotes the portion of the peptide analog library, containing the building units identical to those of the backbone cyclized library, but is devoid of the conformational constraint of the latter.

Certain abbreviations are used herein to describe this 15 invention and the manner of making and using it. For instance, AcOH refers to acetic acid, Ada refers to adamantanacetyl, Adac refers to adamantanecarbonyl, Alloc refer to allyloxycarbonyl, BCIP refers to 5-bromo-4-chloro-3indolyl phosphate, BK refers .to bradykinin, Boc refers to the t-butyloxycarbonyl radical, BOP refers to benzotriazol-lyloxy-tris-(dimethylamino)phosphonium hexafluorophosphate, BPI refers to Bactericidal/permeability increasing protein, BSA refers to bovine serum albumin, Cbz refers to the carbobenzyloxy radical, DCC refers to 25 dicyclohexylcarbodiimide, DCM refers to Dichloromethane, Dde refers to 1-(4,4-dimethyl2,6-dioxocyclohex-l-ylidene-ethyl, DIEA refers to diisopropyl-ethyl amine, DMF refers to dimethyl formamide, DPPA refers to diphenylphosphoryl azide, Dtc refers to 5 5 -dimethylthiazolidine-4-carboxylic acid, EDC refers to N-ethyl-N'(dimethylaminopropyl)-carbodiimide,

EDT

refers to ethanedithiol, Fmoc refers to the fluorenylmethoxycarbonyl radical, GPI refers to guinea pig ileum, HATU refers to [0-(7-azabenzotriazol-l-yl)-1,1,3,3tetramethyl uronium hexafluorophosphate, HBTU refers to 1hydroxybenztriazolyltetramethyl-uronium hexafluorophosphate, HF refers to hydrofluoric acid, HOBT refers to 1hydroxybenzotriazole, HPLC refers to high pressure liquid 14 WO 97/09344 PCTIL9600091 chromatography, IL-6 refers to interleukin 6, IL-6R refers to interleukin 6 receptor, MALDI-TOF MS refers to matrixassisted laser desorption, time-of-flight mass spectrometry, Mts refers to the 4 -methoxy-2,3,6-trimethylbenzenzsulfonyl, NBT refers to nitro blue tetrazolium, NMM refers to Nmethylmorpholine, NMP refers to l-methyl-2-pyrolidonone,

PBS

refers to Phosphate buffered saline, Pmc refers to pentamethylchroman-6-sulfonyl, PNPP refers to p-nitrophenyl phosphate, PPA refers to 1-propanephosphoric acid cyclic anhydride, PyBOP refers to Benzotriazole--yl-oxy-trispyrrolidino-phosphonium hexafluorophosphate, PyBrOP refers to i Bromo-tris- pyrrolidino-phosphonium hexafluorophosphate,

RT

refers to room temperature, SMPS refers to simultaneous multiple peptide synthesis, SP refers to Substance P, SRIF 15 refers to Somatotropin Release Inhibitory Factor, TBTU refers *>to 2-(1H-benzotriazole-l-yl)-1,1,3, 3 -tetramethyluronium tetrafluoroborate, t-Bu refers to the tertiary butyl radical, TFA refers to trifluoroacetic acid, TIS refers to triisopropylsilane, Tpr refers to thiazolidine-4-carboxylic acid, Trt refers to trityl, Ts refers to toluenesulfonyl.

The amino acids used in this invention are those which are available commercially or are available by routine synthetic methods. Certain residues may require special t* methods for incorporation into the peptide, and either 25 sequential, divergent and convergent synthetic approaches to the peptide sequence are useful in this invention. Natural coded amino acids and their derivatives are represented by three-letter codes according to IUPAC conventions. When there is no indication, the L isomer was used. The D isomers are indicated by before the residue abbreviation. List of Non-coded amino acids: Abu refers to 2-aminobutyric acid, Aib refers to 2- amino-isobutyric acid, Cha refers to cyclohexylalanine, Hcys refer to homocysteine, Hyp refers to S-trans-4-hydroxyproline, INal refers to l-naphtylalanine, 2Nal refers to 2 -naphtylalanine, Nva refers to norvaline, Oic refers to octahydroindolecarboxylic acid, Phg refers to phenylglycine, pClPhe refers to p-chloro-phenylalanine, pFPhe 15 WO 97/09344 PCTIIL96/00091 refers to p-fluoro-phenylalanine, pNO2Phe refers to p-nitrophenylalanine, Thi refers to thienylalanine.

Advantages of the Invention According to the present invention, the principles of cyclic peptide libraries have now been successfully applied to the generation of novel mixtures of peptidomimetic compounds, which are characterized in that they incorporate novel building units with modified side chains attached to the alpha nitrogens of alpha amino acids. These novel building units permit the generation of peptidomimetics, that are backbone-to-backbone cyclized and conformationally constrained.

The most striking advantages of this approach are as 15 follows: 1) The method enables cyclization of the peptide sequence without compromising the side chains of the peptide sequence that are involved in biological recognition and functionality. 2) The method allows optimization of the peptide conformation by allowing permutation of the bridge length, direction, and bond type amide, disulfide, thioether, thioester, etc.) and position of the bond in the ring. 3) When applied to cyclization of linear peptides of known activity, the bridge is expected not to be involved in target recognition, thereby creating a site suitable for attachment of tags such as radioactive tracers, cytotoxic drugs, light capturing substances, or any other desired label.

The newly generated libraries, disclosed according to the present invention, now enable screening for varying degrees of conformational constraint, in order to find the optimal backbone conformation of the peptide in performing its role as an agonist or antagonist. This is accomplished by varying both the position of the bridgeheads the positions in the linear sequence of residues that are to be cyclized), as well as varying the length, the direction and the bond type of the bridge between these units.

-16 WO 97/09344 PCT/IL96/0009

I

As exemplified hereinbelow, the libraries according to the present invention enable the identification of conformationally constrained backbone cyclized peptide analogs having significantly improved biological activity compared to the linear peptide .comprising the same sequence of amino acids. The improvement may provide enhanced selectivity to the receptor, or prolonged duration of action, or increased metabolic stability or yet other advantages in comparison to the linear peptide sequence from which the peptide analog is derived.

Methodology The general methodology for preparing the cyclic peptides of this invention involves solid phase peptide 15 synthesis using an orthogonal protection scheme which allows Sfor chain elongation, selective removal of the protecting groups, cyclization of the protected peptides and removal of all side-chains protecting groups with or without cleavage from the resin. It is desirable that the various peptide sequences be present in the libraries in substantially equal -amount.

The coupling reactions are performed by methods to create amide or ester bonds and are performed by methods familiar in the art as described herein. Typical coupling S" 25 reagents are carbodiimides, activated anhydrides and esters and acyl halides. Reagents such as EDC, DCC, DPPA, PPA, BOP, PyBOP, PyBrop, HATU, HBTU, TBTU, HOBT, N-hydroxysuccinimide and oxalyl chloride are typical.

Synthesis of peptide libraries containing more than one building unit, bridge type or amino acid at one or more positions can be performed by different synthetic schemes, as known in the art of peptide synthesis. Preferred methods of generating libraries include the following: -17 WO 97/09344 PCT/IL96/00091 A. Partitioning, coupling, and recombination scheme 1. The resin is partitioned into a number of aliquots corresponding to the number of amino acids or building units used for the defined set used at each position.

2. Each aliquot is coupled exhaustively to a single building unit or amino acid using solid phase methodologies.

3. The synthesis subsequently proceeds by recombining of all resin portions before the next coupling step is performed.

4. Steps 1 and 2 may be repeated as necessary, depending on whether a constant or variable residue is being coupled.

Alternatively, in a divergent synthetic scheme, at any given point in the synthesis each resin aliquot may be treated individually from that point on until the end of the 15 synthesis, thus generating sub-libraries. The synthesis may SI. be carried out in parallel for part or all of the remaining synthetic process, up to and including the cyclization and o i cleavage steps.

B. Coupling of mixtures Synthesis is performed using a mixture of amino acids that are coupled in a certain position to one resin aliquot.

The use of exactly one equivalent of total amino acid and the long coupling time serves partially to correct for the different rates of coupling of the individual amino acids in the mixture and to help ensure that an equimolar mixture of amino acids is obtained at each position. The procedure of U.S. Patent 5,010,175 can also be used.

After completion of the solid phase peptide elongation, by any scheme, portions of the peptide are cyclized, via the bridging groups attached to the backbone amide bond nitrogens of the building units. It is preferable that a portion is retained in the non-cyclized form to serve as control during the biological or other screening assays. This portion of the peptide analog library, which contains the building units identical to those of the backbone cyclized library, but is devoid of the conformational constraint of the latter, is 18- WO 97/09344 PCT/IL96/00091 referred to as the "pre-cyclic". Alternatively, in any of the synthesis schemes, the backbone cyclization step may be performed and additional coupling cycles of amino acid residues may then be carried out.

Portions of the peptide may be cleaved from the resin and protecting groups removed, as required prior to assay of biological activity. The peptides are cleaved from the resin support by methods known in the art, the precise method being dependent upon the characteristics of the resin. It will be understood by those skilled in the art that the removal of certain protecting groups may occur simultaneously with cleavage of the peptide from the resin.

Typically the coupling between the resin and the first amino acid will form an ester bond, which will yield a 15 carboxylic acid group on the peptide when it is cleaved from the resin. HMPB, Rink, PAM, Hycram and hydroxymethyl resins are exemplary. In addition, the carboxy terminal amino acid group may be converted to an amide, an ester or reduced to a terminal alcohol.

20 The reactive functional groups of the side chains of each amino acid or peptide are suitably protected as known in the peptide art. For example, the Boc, Cbz or Fmoc group may be used for protection of an amino group, especially an ao amino group. An alkyl t-Bu, Me), cHex, benzyl or allyl S* 25 ester may be used for the protection of the side chain carboxyl of Asp or Glu. A benzyl, or suitably substituted benzyl, trityl, Alloc or t-Bu group is used to protect the mercapto group of cysteine, or other thiol containing residues; or the hydroxyl of Tyr, Ser or Thr. Cys and other sulfur-containing amino acids may also be protected by the Acm group or by formation of a disulfide with a thioalkyl ethyl mercaptan) or thioaryl group. The benzyl/benzyloxymethyl, or a suitably substituted benzyl/benzyloxymethyl, Boc or formyl group may be used for protection of the imidazolyl group of His; and the Pmc, nitro or a suitably substituted benzene-sulfonyl group Ts, Mts) for protection of the guanidino nitrogen of Arg. The 19 WO 97/09344 PCT/IL96/00091 phthalamido, Boc, Fmoc, Alloc carbobenzyloxy or benzyl group, or suitably substituted benzyl or benzyloxy group, may be used for protecting the (-amino group of lysine. Suitable substitution of the carbobenzyloxy or benzyl protecting groups is substitution with one to five chloro, bromo, nitro, methoxy or methyl groups, usually ortho and/or para, and is used to modify the reactivity of the protective group. These protective groups are removed by such methods as catalytic hydrogenation, sodium in liquid ammonia, hydrazine, base, TFA or HF treatment, as known in the art. The choice of side chain protecting groups is chosen so that they will not be removed under conditions which are used to deprotect the reactive functional group used in the coupling reaction generally the (-amino group) to form the peptide 15 backbone of the peptide chain. The protective group of the reactive functional group is removed prior to coupling each successive amino acid.

The bridging groups of the building units G in Formula IV) are used according to the present invention with an orthogonal protection scheme, such that these protecting groups can be removed selectively, under conditions which do not affect the protecting groups on the side chains or cleavage of the peptide from the resin. This enables backbone cyclization on the resin, which is preferred synthetically.

25 Alternatively, the fully protected peptide may be removed from the resin, and cyclization performed in solution after selective removal of the protecting groups of the building units.

The cyclization reaction is carried out by means of selective coupling the bridging group of one building unit to a bridging group of another building unit or amino acid side chain. By way of example, the PyBOP is particularly useful reagent for conducting the coupling reaction, in case of formation of an amide bond. To form a disulfide bridge oxidative conditions are used.

A typical scheme for preparing libraries according to the invention involves using resin such as TentaGel or Rink 20 resin as the support, Fmoc as the (-amino protecting group, t-butyl based protecting groups for the side chains, and allyl/Alloc for the side chain of building unit. Other schemes of orthogonal protection known to those skilled in the art are obviously applicable as well. Generally, one will calculate the number of amino acids in the amino acid set for each position in the peptide, and will use sufficient resin so that there is at least a five-fold molecular excess of reactive sites on the resin to the number of possible peptide sequences.

When the C-terminal amino acid is variable, it is convenient to begin the synthesis using a mixture of individual aminoacyl peptide resins with an equimolar distribution of the amino acids used. An equimolar mixture of the same protected amino acids can also be prepared. An aliquot of the protected amino acid mixture corresponding to exactly one equivalent of total amino acid is allowed to couple to the resin mixture. The use of exactly one equivalent of total amino acid and the long coupling time 20 serves partially to correct for the different rates of coupling of the individual amino acids in the mixture and to help ensure that an equimolar mixture of amino acids is obtained at each position. At this point, a Kaiser test may be performed to assess the completeness of coupling and 25 recoupling with one equivalent of the equimolar mixture can be performed as necessary.

.i The amino acid sequence scaffold is based on known

S

active sequences from natural or synthetic peptides or proteins.

It will thus be possible to further improve the activity of such known sequences, upon rigidification of the active conformer. In other instances, it will be possible to further improve the activity of other types of peptidomimetics, not involving backbone cyclizations Polymixins) 21 WO 97/09344 PCT/IL96/00091 The application of the present invention is particularly suitable for peptides of 3 up to 14 amino acid residues.

However, it is also useful to define peptide fragments that compete with larger polypeptides having up to 45 to residues. These methods can be used to produce both conformationally constrained agonists and antagonists. They can either optimize the properties of known sequences or generate novel analogs.

•Amino acids in certain positions are replaced by 10 Backbone-Cyclization Building-Units or by natural and nonnatural trifunctional amino acids such as Asp, Glu, Cys, Hcys, Lys, Orn and their D counterparts. Thus positional as well as structural scans are performed by changing the position of cyclization, the link of the ring to the S 15 backbone, the chirality at the position of cyclization, the *ring forming bond, the ring size and the exact placement of I the bond within the ring. These variations may also be performed in conjunction with changing the amino acids sequence of the peptide..

In one preferred embodiment of the present invention, backbone-cyclic peptide libraries were prepared by Simultaneous Multiple Peptide Synthesis (SMPS, Houghten, Proc. Natl. Acad. Sci. USA 82, 5131-5135, 1985) Resin portions were kept separate by capturing them in polypropylene bags, and coupling and deprotection cycles were performed on all bags together in a polypropylene box, except for steps of coupling of different amino acids at the same sites of the peptides. In each bag there was only one (crude) compound by the end of the synthesis.

After completion of the synthesis, samples of resinpeptide were taken form each bag to make mixtures based on structural homology a mixture could be comprised of all peptides with a D-amino acid at a certain position or all peptides with the same ring size etc.). The peptides were cleaved from the resin and screened for biological activity as crude mixtures. Then peptides from the most active mixtures were cleaved separately from the resin, purified by 22 WO 97/09344 PCT/IL96/00091 preparative HPLC, characterized by mass-spectrometry and amino-acid-analysis and assayed for their biological activity.

Backbone-cyclic peptides containing a disulfide bond in the ring were prepared by inclusion of protected -thiol building units in the sequence. Backbone to backbone cyclization was performed by disulfide bond formation between two such building units in a given sequence. Alternatively were backbone to side-chain cyclic peptides prepared by o closing a disulfide ring between the w-thiol group of a building unit and the thiol group of Cys or HCys. Formation of the disulfide bond on the resin was obtained by adaptation of the diphenylsulfoxide-silyl chloride method (Akaji et. al.

J. Amer. Chem. Soc., 114, 4137, 1992). This is done as was 15 presented in the literature (Camarero et. al., Tetrahedron ~Lett., 36, 1137-1140, 1995) for prolonged periods (16-24 h) at room temperature. The yields were not high but were sufficient for biological screening. A backbone-bicyclic peptide library was prepared by combining lactam and disulfide cyclizations. Analogs of [Arg6]SP6-11 where Metll was replaced by an w-thiol containing building unit, Cys or HCys, and Gly9 was replaced by an w-amine building unit were synthesized manually in SMPS bags using Fmoc chemistry. The u-amino group of the building unit in position 9 was protected by Boc. After coupling of this building unit the Boc group was removed and to the c-amine was coupled a second w-thiol building unit or amino acid with its a-amine protected with Boc. Then the Fmoc group was removed from the a-amine of the building unit in position 9 and the synthesis of the peptides was continued. After completion of the synthesis of the hexapeptide chain, a dicarboxylic acid was coupled to the amino terminus and then the Boc group protecting the a-amino group of the c-thiol containing building unit or amino acid was removed and the lactam ring was closed. Then the disulfide ring was closed by the above mentioned solid-phase diphenylsulfoxide-silyl chloride method. Since the yields of these peptides were relatively 23 WO 97/09344 PCT/IL96/00091 low due to side-reactions in the disulfide formation step, the peptides comprising the most active mixtures were resynthesized and cyclized separately after cleavage from the resin by the normal solution diphenylsulfoxide-silyl chloride method.

In another preferred embodiment, libraries are synthesized by the portioning-mixing method (Furka et al.

Int. J. Pep. Protein Res. 37, 487-493, 1991). Typically, in each variable position the resin is split into the 1 0 appropriate number of aliquots, and different amino acids or building units are coupled to each. Any appropriate reaction vessel may be used to contain these aliquots; in a preferred embodiment it is very convenient to use an individual column for each portion of the resin. After the coupling is 15 completed and the coupling mixture is washed out, all or part S" of the resin portions are recombined. Removal of a-N protecting groups (typically Fmoc) is performed on the recombined resin. Further cycles of coupling, and the other steps, are carried out similarly with or without portioning and mixing of the resin. Preferably, in this scheme of production, the library consists of several sub-libraries which differ in one or more amino acid residue, building unit and/or bridge. The final resin portions (sub-libraries) are cyclized to yield backbone cyclized mixtures or left as precyclic mixtures. After removal of side-chain protecting groups and optional cleavage of the sub-library peptides from the resin, screening of the sub-libraries set leads to identification of an optimized sub-library. Further synthesis and screening cycles lead to the optimized backbone cyclized peptide. In each successive synthetic cycles, the complexity of the mixture is smaller.

In another preferred embodiment libraries are synthesized on non-cleavable resins to yield solid-phase supported libraries. Diversity of bridges and amino acids sequence is achieved by the positional scanning method (reviewed by Pinilla et. al. ibid.).

24 WO 97/09344 PCT/IL96/00091 Examples Conformationally constrained peptidomimetic libraries have been constructed based on the sequences of a number of known biologically active peptides. The following peptides serve as examples that are intended to illustrate how to make and use the libraries and methods of this invention and are in no way to be construed as a limitation.

General synthesis of libraries of somatostatin analoQs.

BPI

10 analogs and interleukin-6 inhibitory Deptide analos The libraries were synthesized on TentaGel amide Resin (substitution level of 0.2-0.3 mmol/g) using conventional f solid-phase peptide synthesis (known to those skilled in the art). In most cased NMP was used as a solvent, DMF in few 15 cases. Synthesis scale was 0.2-2 (mole for each peptide in library or sub-library. Unless mentioned, all reactions were performed at room temperature.

In each coupling step where more then one amino acid had to be coupled, the resin was divided into the appropriate number of portions and different amino acid was added to each portion.

Coupling was performed, twice for each position with 3 molar excess of each amino acid, 3 molar excess of PyBrop and 6 molar excess of DIEA for duration of 1-16 hours.

All amino acids were protected with FMOC in their (-amine.

Side-chain protections were as follow: His(Trt); Lys(Boc or Dde); Orn(Boc); Ser(tBu); Thr(tBu); Tyr(tBu).

After double coupling, the resin portions were washed, recombined and FMOC deprotection was performed using piperidine in NMP for total of 20-40 minutes. After additional washes the resin was divided again (if necessary) for the coupling of the next amino acid/s.

Before cyclization, the Allyl/Alloc protection of the amine and carboxyl of the building units were removed by treatment with a solution of 2 mole equivalents (one for each Allyl/Alloc molecule in peptide), of Pd(PPh3)4 dissolved in chloroform containing 2.5% AcOH and 5% NMM for 2-2.5 hours or WO 97/09344 PCT/IL96/00091 twice for 1 hour, resins were washed with the above solvent without the palladium before and after treatment, additional washes with NMP were made at the end of the removal process.

For cases were the backbone-cyclic library and the precyclic libraries are synthesized simultaneously, the resin was divided into separate portions before cyclization and cyclization was performed only for the "cyclic library" portion. The corresponding linear library was synthesized separately because it contains non-modified amino acids 10 instead of the building units. Cyclization was performed twice or three times, each with 3 molar excess of PyBOP and 6 molar excess of DIEA for 2-16 hours with NMP washes between and after coupling.

The peptides were cleaved from the resin portions after 15 washes with DCM, by double treatment with TFA 70%, H20 TIS EDT DCM (mixture A) or TFA 70%, H20 TIS 1%, Phenol DCM (mixture B) or 60% TFA, 10% H20 and 30% DCM (mixture C) plus additional wash with neat TFA. The three cleavage solutions of each resin portion were collected together, evaporated with nitrogen stream, 0.5-1 ml of were added to each sample that was then freeze-dried. The peptide mixtures were then partially purified on C-18 SEP-PAK (Millipore Corp.) using 0.1% acetic acid or TFA in H20 as buffer A and 50-80% CH3CN in 0.1% acetic acid H20 as buffer B and freeze-dried.

Yields of semi-purified peptide mixtures were generally 10-60% of initial synthesis scale. Optimization of synthetic procedures during scale-up will lead to higher yields.

Each sub-library synthesized was characterized by mass spectrometry (MALDI-TOF MS), and amino acid analysis.

The building units are abbreviated by the three letter code of the corresponding modified amino acid followed by the type of reactive group (N for amine, C for carboxyl), and an indication of the number of spacing methylene groups. For example, Gly-C2 describes a modified Gly residue with a carboxyl reactive group and two methylene spacer, and Phe-N3 -26- WO 97/09344 PCT/IL96/00091 designates a modified phenylalanine group with a amino reactive group and three methylene spacer.

General screening of libraries of somatostatin analogs,

BPI

analogs and interleukin-6 inhibitory peptide analogs: Somatostatin libraries synthesized in these schemes are typically tested in-vitro for their inhibition of the natural peptide (SRIF-14) binding to its 7-transmembranal receptors, for their influence on second messengers and cell growth and 10 in-vivo for inhibition on hormones and enzymes secretion.

BPI

libraries synthesized in these schemes are tested for their inhibition of fungi growth. IL-6 libraries are tested for their influence on the native protein (IL-6) binding to its transmembranal receptors (IL-6R and gpl30) and for inhibitory 15 activity on IL-6 action. Both libraries synthesized in these schemes are tested for their in-vitro and in-vivo metabolic stability.

SMetabolic stability tests as parameter for selection: Libraries are tested for their stability to enzymatic degradation by incubation in serum or in tissue homogenate, separation of the proteins and recording of the peptide peaks by HPLC before and after incubation. The peptide peaks that are not changed with increased incubation time are most stable for degradation. These peaks are separated and characterized by mass spectrometry, N-terminal sequence and comparison to purified peptide peaks. In this way the most stable peptides from library or sub-library are rapidly identified.

General synthesis of bradykinin and Substance P analogs Libraries were synthesized on such resins as hydroxybenzyl resin with 0.39 meq/gr substitution level (BK libraries) or on 4 -methylbenzhydrylamine resin with 0.57 meq/gr substitution level (SP libraries) using "tea-bag" simultaneous multiple peptide synthesis (Houghten, Proc.

Natl. Acad. Sci. USA 82:5131-5135, 1985). Usual solvents for 27 WO 97/09344 PCT/IL96/00091 peptide synthesis such as NMP or DMF were used. Synthesis scales were 20-60 mmole for each peptide. All reactions were performed at room temperature.

Coupling was performed with 6 molar excess of each amino acid, 6 molar excess of coupling agent and 12 molar excess of DIEA. for duration of 2-3 hours. Coupling agents were HBTU for normal Fmoc/Boc-amino acids couplings, PyBroP for couplings of and building-units and TBTU for lactam ring cyclization. Couplings to building units and lactam ring o: cyclizations were repeated 3-4 times. Amino acids were protected with Boc or Fmoc on the a-amine. Side-chain protections were as follow: Arg(Tos), D-Arg(Tos), Hyp(Bzl), S Glu(tBu), D-Glu(t-Bu), D-Asp(t-Bu), Ser(Bzl). Boc, t-butyl and benzyl were used for the protection of the w-amino, 15 carboxyl and sulfhydryl groups of the building unit.

.Fmoc deprotection was performed with 20% .piperidine in DMF for 30 minutes once or twice. After the completion of peptide elongation, the Boc and t-Bu protecting groups were removed with 55% TFA in DCM once for 2 min and a second time for 30 min.

In cases where the cyclic and pre-cyclic peptides were synthesized simultaneously, the resin was divided into two separate portions before cyclization, and cyclization was performed only on the "cyclic library" portion using 6 fold excess of TBTU and 12 fold excess of DIEA. Cyclization was repeated until negative Kaiser test. The corresponding precyclic library was either left intact, or the amine and Scarboxyl groups were blocked by acetylation and reaction with methylamine respectively. Acetylation was performed with molar excess of acetic anhydride in DMF or NMP and 1 equivalent of DMAP as catalyst. Reaction with methylamine was carried out by activation of the free carboxylic group for min with 10 molar excess of DIC (0.5M in DCM) and HOBT in DMF) followed by addition of 10 molar excess of solution of methylamine in ethanol.

Peptide-resin mixtures based on structural homology were prepared using samples from each tea-bag. They were cleaved -28 WO 97093"PCTIL96/00091 from the resin using HF/anisole at 0-5 0 C and screened f or biological activity as crude mixtures.

Ecreening of bradykinin and Substance P libraries-for bioloCicaL activity: Bradykinin and Substance P backbone cyclized libraries synthesized in these schemes, are typically tested for their agonist or antagonist activity on Guinea Pig Ileum (GPI) contraction (Sawutz et. al. PNAS. 91, 4693-4697 1994).

BRADYKININ

ANALOGS:

Example 1 cyclo [-(CH 2 n-NH-CC-

(CH

2 k-NH-CC-

(CH

2 m-ODAgAgPoHp Gly-Phe-Ser-D-Phe]-H COAt-O and pre-cyclic aaos Formula: cyclic: 0 .0 C

(CH)-C-N

H

(CH 2 )m (6H 2 )n C D-Arg-- Arg Pro Hyp Gily- Phe Ser -D-Phe N G ly -krg OH 0 -29- WO 97/09344 PCTJIL96,'00091 pre-cyclic: 0 0 0 C-N-CH 3 H 3

H

H H (C 2

N

2 )m

(OH

2 )n 10 C- D-Arg- Arg -Pro Hyp Gly -Phe Ser D-Phe -N -G y -Arg

OH

k m ni 2,3,4,6

PEPTIDES

Ppie kMn ring Mass Mass number (caic.) (obs.) 20 201 0 2 2 32 1317.4 1317 2404 3 42 1472.7 1471 212 5 2 4 6 1476.7 1485 203 0 3 6 37 1500.7 1300 30 WO 97/09344 PCTIIL96/00091 _______PRECYCLIC PEPTIDES Peptide k m n Mass Mass numbe r (obs.) 214 0 2 2 1389.5 139o 215 0 3 2 1403.5 1403 216 0 4 2 1417.5 1417 217 0 4 3 1431.5 1432 218 0 4 4 1445.6 1446 219 0 3 6 1459.6 1460 220 0 4 6 1473.6 1474 221 1 4 4 1502.6 1502 222 1 3 6 1516.6 1516 223 1 4 6 1530.6 1529 224 2 4 6 1544.7 1 544 225 5 2 6 1558.7 226 6 1: 571 7 No biological activity of this mixture has been found.

.V*o* Example 2 Ada-D-Arg-Arg-cyclo.. n-NH-CO-

(CH

2 k-NH-.CO-

(CH

2

M-CO-N-CH

2 CO-Hyp-Gly-Leu-N- 3 CH 2 -CO-D-Phe-Leu-Ag-OH and pre-cycl ic analogs.

31 WO 97/09344 ForMUla: cyclic: PCTIL9/00091 C -N-(H 2 N

H

(CH

2 m (CH

I

2 )n Ada -D-Arg -Arg- N- Gly- Hyp- Gly- Leu- N- Gly- D-Pht- Leu- Arg-- OH precyclic:

COOH

(CH 2 )m HN- -C 2 N H 2 (CH 2 )n Ada -D-Arg-Arg- N- Gly- Hyp- Gly-- Leu- N- Gly-- D-Phe--- Leu-- Arg- OH k In 2,3; n 2,3,4,6 32 WO 97/09344 PCTIL96/00091 CYCLIC PEPTIDES Peptide k M n ring size number 253 0 2 2 19 254 0 2 3 255 0 3 3 21 *go:256 0 3 4 22 0 ,257 0 2 6 23 g* 10 .:0258 0 3 6 24 *.259 2 3 3 :*se*f 4t260 2 3 4 26 261 2 2 6 27 15 262 2 3 6 28 263 5 3 4 29 0.0.

264 5 2 6 265 5 3 6 31 Kd (mlXtUre) =7 9.5 AJ.o-m 33 WO 97/09344 Formula: cyclic: PCTIIL96,ooog

I

HH

see* *00 000

(CH

2 )m (CH 2) D-Arg--Arg--N- GyHyp--- Gly- Leu- Gly-- D-Phe-- Leu- Arg OH precyclic: S. S S S

OS

0

SOS...

0

COCH

-(CH

2 2

(OH

2 )m

(CH

2 )n D-Arg -Arg- N--Gly-Hyp Gly-Leu..- Gly- D-Phe-- Leu- Arg- OH k 2,5; m 2,3; n 2,3,4,6 34 WO 97/09344 PCTIIL96/0009

I

Examp~le 4 Ada-D-Arg-Arg-cyclo

[-(CH

2 n-NH-CO-

(CH

2 k-NH-CO-

(CH

2

M-CO-N-CH

2 CO-Hyp-G1Y-Phe-.N-]-CH 2 -CO-D-Phe-Phe-Arg.OH and pre-cyclic analogs.

Cyclic:

C-N-(CHH

C. (OH 2 C- N (CH H 2 )n (CH 2 )m Ada -D-Arg-Arg-- N- Gly-- Hyp- Gly- Phe- Gly- D-Phe- Phe- Arg OH precyclic:

COOH

(CH 2 )m (CH 2 )n Ada -D-Arg-Arg- N- Gly- Hyp- Gly- Phe- IN- Gly- D-Phe- Phe- Arg OH.

k 0, 2, 5; in 2,3; nl 2,3,4,6 35 WO 97109344 WO 9709344PCTIIL96/0009

I

PEPTIDES

Peptide k m n ring Size number 305 0 2 2 19 306 0 2 3 307 0 3 3 21 308 0 3 4 22 309 0 2 6 23 310 0 3 6 *24 311 2 3 3 312 2 3 4 26 313 2 2 6 27 314 2 3 6 28 315 5 3 4 29 316 5 2 6 317 5 3 6 31 No biological activity''of this mixture has benfound.

Example H-D-Arg-Arg-cyclo n-NH-CO- k-NH-CO- (CH 2 m-CO-N-CH.- CO-Hyp-G ly-Phe-N-) CH-CO-D-Phe-Phe-Arg.OH and pre-cyc lic analogs.

36

U

WO 97/09344 Formula: cyclic: PCT/1L96/000 9 1

H

(CH 2 )m

(CH

2 D-Arg- Arg-N GY-- Hyp- Gly-- Phe- N -Gly- D-Phe-- Phe- Arg-- OH precyclic:

COOH

HN

-~C

2 NH 2 (CH 2 )n

(CH

2 )m D-Arg--Arg-N- GIy-Hyp-GIy-phe-N- Gly- D-Phe-- Phe-- Arg-

OH

k 0,2,5; m 2,3; n =2,3,4,6 37

I

WO 97/09344 PCT/1L96f00 0 9 1 Example 6 H-D-Arg-Arg-cyc 0 (CH 2 fl-CO-NH-

(CH

2

M-N-CH

2

C

0 -Hyp-Gjy-.Ph~e Xaa-)-D-Phe-Phe-Arg.OH and pre-cyclic analogs.

Formula: cyclic: *b HN

C

(OH 2 )m (CH 2 )n D-Ar-A.7 Gl-Hy~lyPhe- D-Phe-Phe -Arg-

OH

H H0 pre-cyclic:

NH

2 (CH 2 )m

COOH

(CH 2 )n D-Ar-ArgN-Gl- Hyp-Gly- Phe- C- C- 0-Phe- Phe- Arg--

OH

H H0 mn 2,3,4,6; n 1, 2; Xaa D-Asp, Glu 38 WO 97/09344 WO 9709344PCTIIL96/00091

I

CYCLIC PEPTIDES Peptide Xaa Tf nl ring number 331 D-Asp 2 1 19 332 D-Asp 6 1 23 333 Glu 3 2 21 334 Glu 4 2 22 335 Glu 336 JGlu j 6 inhbiton(mixture) -at 1U-M.

86% inhibition (peptides 331-332) at 5x10-5m.

1696 inhibition (peptideS 333-336) at Peptide 331 was found to be inactive.

Kd (peptide 332) 2Xl0- 5

M.

PRECYCLIC PEPTIDES Peptide Xaa m n number 337 D-Asp 2 1 338 D-Asp 6 1 339 Glu 3 2 340 Glu 4 2 341 -Glu 2 2 342 Glu I 6 No biological activity of this mixture has been found.

Example 7 Ada-D-Arg-Arg-cycl 0 (CH 2 n-CO-NH-

(CH

2 rn-N-CH 2 -CO=Hyp-Gly..Phe-.

Xaa-3-D-Phe-Phe-Arg.OH and pre-cyclic analogs.

39 WO 97/093" F'ormula: cyclic: PCTIL96/00091

NH

2

(CH

2 )m

COOH

(CH 2 )n H HO pre-cyclic:

NH

2 (CH

H

2 )m

COOH

(CH 2 )n Ada- D-Arg-Arg- N- Gly- Hyp. Gly- Phe- N- C C D-Phe- Phe- Arg- OH HHO0 M 2,3,4,6; nl 1, 2; Xaa -D-Asp, Glu 40 s.

WO 97/09344 PCTIL96/0009 1

PEPTIDES

Peptide Xaa M n ring numiber 343 D-Asp 2 1 19 344 D-Asp 6 1 23 345 Glu 3 2 21 346 Glu 4 2 22 347 Glu 1 2 2 1 348 -T Glu f 6 2 24 1 Kd (mixture) Bxlo'?m.

78% inhibition (peptides 343+344) at 10&sm.

54t inhibition (peptides 345+348) at 5x10- 5

M.

PRECYCLIC

PEPTIDES

Peptide Xaa M n number 349 D-Asp 2 1 350 Glu 2 2 351 Glu 3 2 352 Glu 4 2 353 D-Asp 6 1 354 Glu 6 2 16t inlhibition (mixture) at 10- 5

M.

41 WO 97/09344 PCTIIL96/00091 Example 8 D-Arg--Arg-Ccco-

(CM

2 n-CO-NH- (CHO) I-N-CH 2 -CO-Hyp-G ly-Phe-Xaa- )-D-Phe-Phe-Arg-OH Formula: HN

-C

0 to **og: (CH 2 )n (CH 2 )m is W -D-Arg-Arg- N- Gly- Hyp- Gly- Phe- C C- D-Phe- Phe- Yaa-Arg OH HH 0 W H, Adac (Adamantanecarboxylic acid) 2m 2,3,4,6; n 1,2; Xaa D-Asp, D-Glu; (Octahydroindole3..carboxyi ic acid Yaa =Phe, Qic Synthesis: Peptides were prepared in SMPS bags, each one containing 60 mg Hydroxybenzyl resin (0.39 meq/gr). Because of the biological activity of the mixture, several new mixtures and then separate peptides were cleaved separately from the resin for biological screening.

42 WO 97/09344 PCT/1L96/00091 a a V. a a *9a~

CYCLICPEPTIDES

Peptide W Xaa Yaa in n ring number _____size 368 H D-Asp, Qic 2 1 19 369 H D-Glu Phe 2 2 370 H D-Glu Phe 3 2 21 373 H D-Asp Phe 3 1 374 H D-Asp Phe 4 1 21 371 H D-Glu Phe 4 2 22 372 H D-Glu Phe 6 2 24 375 H D-Asp oic 6 1 23 376 Adac D-Asp Phe 2 1 19 377 Adac D-Asp Qic 2 1 1 378 Adac D-Asp Phe 6 1 23 379 Adac D-Asp Ic 6 1 L 23 Biological results: peptides 373+374 20% inhibition at iO' M4.

peptide 373 15% inhibition at 10-1 M.

peptide 374 18% inhibition at 10-7 M.

peptide 376 28% inhibition at 3.0-5 M.

peptide 378 Kd 8X10- 7

M.

peptide 368 no activity was found.

peptide 375 18% inhibition at 10-' M.

a. a a a a.

a SUBSTANCE

P

6 -1 ANALOGS: Exami~le 9 Ac-Arg-PhePhe-cyco..[

(CH

2 n-CO-NHi- m--CH 2 -CO..Leu-.Xaa]..

NH

2 and Ac-Arg-Phe-Phe-cyclo..

(CH

2 n-CO-NH-

(CH

2 m-N-CH 2 -CO-Leu-

N-]-CH

2

-CO-NH

2 and their pre-cyclic analogs.

-43 e J. WO 97f093"4 Formula: cyclic: PCT/1L96/00091 HN C HN C (CH 2 )m (CH 2 )n Ac-Arg- Phe-Pho.N- Gly Lou- N- Gl)y NIft (CH 2 (CH 2 Ac-Arg-PNO.Phe.N- Gly- Lou- Xaa- l 9 *9

S

.9 9 0*99 a 9. S S 9 9 9 9.

*9 a pre-cyclic: 0 0

H

3 C- C- HN C- N-CH 3

H

(CH

2 )n

(CH

2 Ac-Arg-- Phe-Phe-N- Gly- Leu- N- GIy NFJ 0

H

3 C- HN C N CH 3 (CH 2 (CH 2 )n Ac-Arg-Phe-Phe-N- Gly Lou- Xaa- NP2 9 im 2,3,4,6; n 1,2,3,4,5; Xaa =L-Asp, L-Glu, D-Asp, D-Glu Synthesis: Peptides were prepared in SMPS bags, each one containing ioo mg MBHA resin (0.57 ineq/gr) and screened for biological activity on GPI. Peptides from the most active cyclic and pre-cyclic mixtures (5C and 5L respectively) were cleaved separately from the resin, purified by preparative HPLC, characterized by TOF-MS and AAA and detected for their biological activity on GPI.

44 WO 97/09344 PCT/1L96/ooo9l

MIXTURES

Mixtre NmberEC 50 (nM) number Structure Of Wtot Wt peptdes atropine atropine' 1C 2C 3C 4C 1L 2L 3L 4L 'C Xaa=L-Asp, L-Glu 2C Xaa=D-Asp, D-Glu 3C Xaa=Gly units Ring size=13,14 4C Xaa=Gly units Ring size=15,16 SC Xaa=Gly units Ring size=17,18,20 iL Xaa=L-Asp, L-Glu 2L Xaa=D-Asp, D-Glu 3L Xaa=Gly units Ring size=13,14 4L Xaa=Gly units Ring size=15,16 5L Xaa=Gly units 8 8 3 4 5 8 8 3 4 5 8 5000 nd 8 >10, 000 nd 3 >10, 000 nd 4 >10, 000 nd 5 3000 8 ~600 8 4000 3 1600 4 >10, 000 nd n. d.

n. d.

n. d.

n. d.

4000 1000 3000 1000 n. d.

750 i5 E ndo=not detected when the value without atropine was equa toor bigger than 5000 nM.

Example Bicyclic SP.-11 analogs.

Formula: 1=3,4; m=3,4; n=1,2; p1,f2f3,4; X=L-Cys, DL-HCys, N-(2thioethylene) Gly Synthesis: Peptides were prepared in SMPS bags, each one containing 100 mg MBHA resin (0.57 meg/gr). The (-amino group of the building unit in position 9 was protected by Boc.

After coupling of this building unit to Leulo the Boc group was removed and to the w-amine was coupled a second S-benz-yl protected w-thiol building unit or amino acid with its a-

I

WO 97/09344 PCT/IL96/00091 0 O (CH S

N-CH-(CH

2 )S 6H2 s c= S 1

(CH

2 NH

(CH

2 IH CH-) O2n (OH) 2 I H2)m i (CH2)m H 2 n C- Arg- Phe-Phe--Gly-Leu NH C-Arg- Phe-Phe-N-Gly- LeuX- NH o0 0 amine protected with Boc. Then the Fmoc group was removed from the a-amine of the building unit in position 9 and the Ssynthesis of the peptides was continued. After completion of the synthesis of the hexapeptide chain, a dicarboxylic acid was coupled to the amino terminus and then the Boc group Ii protecting the a-amino group of the -thiol containing building unit or amino acid was removed and the lactam ring was closed with 6 eq of TBTU and repetition of cyclization 3 times. Then the disulfide ring was closed by the above mentioned solid-phase diphenylsulfoxide-silyl chloride method. Peptides mixtures were cleaved from the resin using HF/thioanisole at 0-5 0 C and screened for biological activity on GPI. Since the yields of these peptides were relatively 25 low due to side-reactions in the disulfide formation step, the peptides comprising the most active mixture (M4) were resynthesized on 500 mg of resin and cyclized separately after cleavage from the resin by the normal solution diphenylsulfoxide-silyl chloride method.

Example 11 A library of bicyclic analogs with varied bridges size was synthesized based on the general formula: 46 WO 97/09344 PCT/IL96/000 9 1 0 0

N-(CH

2

S

N--CH-(CH

2 S

CH

2 C= S C=o S

(CH

2 1 NH

(H

2 1

NH

CH

2 )m (CH 2 n

(CH

2 2)m (CH2) m C-Arg-Phe-Phe-N-Gly-Leu-X-NH 2 C-Arg-Phe-Phe-N-Gly-Leu-X-NH 2 1 0 1 3,4; m 3,4; n 1,2; p 1,2,3,4 X L-Cys, DL-HCys, N-(2-thioethyl)Gly Peptides were prepared in SMPS bags, each one containing 100 mg of MBHA resin (0.57 meq/gr.). The e-amino group of the building unit in position 9 was protected by Boc. After coupling of this building unit to Leu'" the Boc group was removed and to the c-amine was coupled a second S-benzyl protected w-thiol building unit or amino acid with its aamine protected with Boc. Then the Fmoc group was removed from the a-amine of the building unit in position 9 and the :i synthesis of the peptides was continued. After completion of the synthesis of the hexapeptide chain, a dicarboxylic acid was coupled to the amino terminus and then the Boc group S..i protecting the a-amino group of the w-thiol containing building unit or amino acid was removed and the lactam ring was closed with-6 eg of TBTU and repetition of cyclization 3 times. Then the disulfide ring was closed by adaptation of the diphenylsulfoxide-silyl chloride method to solid-phase synthesis. Peptides mixtures were cleaved from the resin using HF/thioanisol at 0-50C and screened for biological activity on GPI. The activity found is summarized in the table below. In order to verify that the activity of the single peptides was not significantly different than that of the mixtures, and in order to increase the overall yield, the 47 WO 97/09344 PCTIL96/0009 1 peptides comprising mixture M4 were re-synthesized on 500 mg of resin and cyclized separately after cleavage from the resin by the regular solution diphenylsulfoxide-.silyl chloride method. The peptides were purified by RP-HPLC and their integrity was confirmed by. TOF-MS. The activity of the individual peptides were in the same range of that revealed by the peptide mixtures.

Biological activity of Deptide mixtures Ring size EC (tM) Mixture No. of disulfide amide Without Wt peptides atropin atropin I2trodction 22 8 1 2 .91 0

B

3 is an amino terinl 2rcobinn framen of.th natra 520~ cai2i proei batrcia/e.eblt 26:85-82 Th 2021 2 3 frgmn has 7l.h2atbctra b:me liner peptide:hlca L~ringLef 22 atomsGlnlyu..pe..i2 (a12.inoan i t5216min thecobinant seruenet servea asica secetfori proucing backboeciclpepteaidet lahresmin theaim fofn devepn anti-fungal aetidty.iTei 48 WO 97 0 9344 PCTIL96/00091 drugs with higher potency, less toxicity and longer half-life than linear peptides.

Usually, for identifying the amino acids critical for activity and those that might be replaced (by building units in our case), one would perform an "Alanine scan" substituting each amino acid in the sequence by Alanine and testing the influence on the peptide activity. Because of the fact that no information was available on the conformation and the structure-activity-relationship of the basic active linear deca-peptide we decided to define the optimal cyclization points within the linear sequence directly by synthesis of backbone-cyclic peptide libraries.

The first BPI library that was synthesized

(IG-BPII),

contained various cyclization points between positions 153- 15 160 (because of synthetic and rational reasons, the Lys .residues of positions 152 and 160 were not substituted). The goal was to determine whether a particular bridge position is favored and which amino acids in the linear sequence can not be substitute. The backbone-cyclic, the pre-cyclic and the 20 linear (actually a double "Glycine scan"), libraries were synthesized and tested. The anti-fungal results, indicate that the activity was preserved to a significant extend in the cyclic peptides. Overall, pre-cyclic peptides were less active than either the corresponding backbone cyclic peptides or linear peptides. Sub-library A6 in which the backbone cyclic peptides were more active than the linear, was the most interesting sub-library, although the differences S• between the four backbone cyclic sub-libraries were not large. The information obtained from the backbone-cyclic library with additional information from separate backbonecyclic analogs, served as basis for the design of the next BPI backbone-cyclic libraries.

Biological evaluations of BPI libraries: The BPI libraries were tested for their anti Candida albicans activity in an in-vitro radial diffusion assay.

Briefly, candida are incorporated into agarose and a series 49 WO 97/09344 PCT/IL96/00091 of wells are punched into the solidified agarose. A small volume of each library/sub-library sample (serially diluted) is placed into each well and allowed to diffuse into the agarose. An overlayer is then poured over the plate and the assay is incubated overnight. Fungicidal zones are measured with a micrometer for each sample dilution. The amount of peptide added to the well that create a net 30 mm2 zone gives the recorded activity result. For a given sample to create a radial diffusion zone, the candida must be killed, therefore this assay distinguish between fungicidal and fungistatic compounds.

In order to validate positive signals of the anti-fungal tests, and to eliminate non-specific signals, library samples of somatostatin-peptides that were synthesized and handled in 15 the same procedures and assume to contain the same contaminants, were tested in the same assays as negative control samples. These samples had no activity in any of the anti-fungal assays.

In addition, the sub-library samples are tested in the radial diffusion assay after incubation in human serum for testing the metabolic stability of these samples and comparison between the stability of backbone-cyclic vs. precyclic and linear libraries.

The antifungal activities are calculated based on the concentration of total peptides in each sub-library mixture.

However, each sub-library is composed of different peptides S. that may have different activity. The activity of the best peptide in any given sub-library might therefore be higher lower amount of peptide), to the extent of the given value divided by the number of peptides per sub-library. In addition, the activity values of purified individual peptides might be better due to existence of salts and impurities in the total weight of the sub-library used for calculation of the concentration.

50 WO 97/09344 PCT/IL96/00091 Solid-phase-release assa for anti-funal and anti-bacterial activit evaluation of BPI and other entide libraries: 1. Peptides are anchored to the beads by a linker that is cleavable by natural pH treatment (Salmon et. al. Proc.

Natl. Acad. Sci. 90, 11708-11712, 1993), the beads are placed in agarose as for radial diffusion assay and the peptides are cleaved to the surrounded media and will inhibit the fungi growth.

2. The peptides are synthesized on non-cleavable linker the beads are placed as above into the agarose and the peptides will inhibit the growth of the fungi or bacteria by binding to essential factors (enzymes etc.) in the media, or cell membrane components.

15 Table I summarize some of the libraries of BPI that were synthesized and characterized. Position numbers of amino acids in the BPI peptides are based on the sequence of the native BPI2 3 protein.

51 WO 97/09344 WO 9709344PCT/1L96/00091 Table I. The composition of several BPI libraries.

Namne Type LibrarSequence per position i I i rr i c-7 i ii 1 IO LU- 6 BPI11 backone -cyclic

LYS

Gly-C2 Bie Gly- Gin Gly Leu Gly- Phe Gly-N2 Phe Gly-N2 ~His Gly _N2

ITT

Gly Lys Gly -N2 Ly 161 Lys Lys pie--cyclic 1Lys Trp Gly-C2 Leu Gly- Gin Gly Leu Gly- 0

S

*6@#06 61 0**6 0@ 6606 6 *6 6 @6 66 06.0

SI

**06 1.A6 I- I _2 I- -N2 linear Lys Trp Leu Bie Gin Leu Phe His Lys Lys.

IGlv Gly Gly GIV Glv Gl' GIv Gly IG- backbone Lys Ti-p Lcu le Gly Leu Phe His Gly Lys BP13' -cyclic Gly -C2 DPhe -N2 Ala Phgu none PNO2Phe FPhepre-cyclic Lys Ti-p Leu le Gly Leu Phe His Gly Lys Gly -C2 DPhe -N2 Ala PhgL Des pWO2Phe backbone FPhe- 10- bakoeLys 2Nal Gly- lie Gin Leu Phe Gly Lys Lys BP14 -cyclic D2Na1 Cl -N2 INal Gly. Gly DINaI C2 -N3 Gly- Gly N2 -Cl Gly- Gly I_ N3 _-C2 I pre-cyclic Lys 2Na] Gly- lie Gin Leu Phe Gly Lys Lys D2NaI C1 -N2 INal Gly- Gly DINal C2 -N3 Gly- Gly N2 -Cl Gly- Gly I N3 I_ All peptides have an amide C-terminal *0 0 01 60 0 004060 6 52 SUBSTITUTE SHEET (RULE 26)

I,

WO 97/09344 PCT/IL96/00091 Example 12: IG-BPI1 LIBRARY This library was synthesized with the aim of finding the best position of the bridge in the basic linear deca-peptide.

In each of positions 153-160 either a native amino acid or a building unit (Gly-C2 in positions 153, 154, 155 or 156 and Gly-N2 in positions 157, 158, 159 or 160) was coupled, yielding four sub-libraries including four peptides in each.

The sub-libraries differ between them in the position of the Gly-C2 unit, while peptides in each sub-library differ in the position of the Gly-N2 unit. The linear library contain nonmodified Gly instead of the building units thus, serve as indication for the necessity of the linear peptide's sidechain groups for activity. The synthesis scheme and the antifungal activities of the cyclized, precyclized and linear 15 sublibraries are illustrated in the following: :i -53 WO 97/09344 PCT/IL96/00091 IG-BPI 1-LIBEhRY Resin Position If 161 Lys

Y

160 Gly-N2

Y

159 His

V

158 Phe

Y

Gly-N2 Phe *m* Gly-N2 -4YA- Loui Vl-N .Recombine and Split Gly-C2 Gin

V

Gly-02 Lue

V

Trp lie

A-.

Trp Gly-C2 LYS Lys Amnount g) to create a 30 mm fungicidal zone: Sub-library: Al A3 A5 A6S Linear: 2 7 18 1s Precyclic: 27 36 45 66 Cyaic: 12 17 30 9 54 WO 97/09344 PCT/IL96/00091 As can be seen from the anti-fungal activity results, the backbone-cyclic peptides have improved activity over the pre-cyclic peptides. In one case, sub-library A6, the activity of the backbone-cyclic peptides is even better than the linear sequence.

Example 13: IG-BPI4 LIBRARY The composition of this library, as illustrated in the following scheme was based on an active peptide (synthesized and tested separately) with the sequence: Lys-DINal-[Gly-C2- Ile-Gln-Leu-Phe-Gly-N2]-Lys-Lys-NH2. With the aim of finding the best bridge size and orientation, four different building units (Gly-Cl, Gly-C2, Gly-N2 and Gly-N3), were used for 15 cyclization between positions 154 and 159. Simultaneously, the influence of different Naphtylalanine (Nal) residues at position 153 was also evaluated. The 4 sub-libraries differ in their residue at position 153 and the peptides (total 32) in each sub-libraries differ in their bridge type or size as illustrated in the following scheme, together with the antifungal activity of the sublibraries. For rapid identification of the preferred bridging building unit at position 154, portions from each of the four peptide-resins (with positions 161-154), after coupling of the building S. 25 units, were removed before recombination and kept. After identification of the active sub-library (by the anti-fungal assay), the "best" Naphtylalanine residue will be coupled to each of the 4 resin portions. After coupling of Lys to each (position 152) portion, the new 4 sub-libraries will be tested for their activity.

55

I

WO 97109344 IG-BP14-LIBRAY PCTIIL96/00091 Position 161 160 159 158 157 Gly-N3 Resin

Y

Lys

LYS

SPhe Leu Gly-N2

A'

Gty-CI Cly-C2 9 04 4

V

156 Gin 155 lie 154 Gly-Ol Gly-C2 Gly-N2 GyN 153 DIINaI 1 Nal M2al MNal Y V V

V

152 LYS Lys Lys Lys Sub-library: A B C

D

Amount (pg) to create a 30 mm 2 tungicidal zone: precydlic: 7 7 22 23 cyclic: 8 8 18 6 16 Peptides in eadh sublibrary.

56 WO 97/09344 PCT/IL96/00091 Example 14: YS-BPI-9 library This library aims to scan the preferred bridge size/type, defined by different building units at positions 159 and 153, of eight different analogs (defined by amino acids at positions 159, 158 and 156). The library format is illustrated in the following scheme: 57

U

WO 97/09344 YSflLB PCT/IL96/00091' ibrarv Lys Des Lys (B) GiyN2Gly-N3 GiylGy-C3 Phe P-NT-12 Phe Phe p-NI-U -Phe Phe p-NH2 -Phe Phe p-NI-U -Phe LeiLeu Leu Gin Glu Gin Giu Gin Giu Gin Glu lele Bie Be Lu Leu I.AI eu Lcu lY-CI Giy-r22 Gly-C3 Gly-Ci Gly-C2 GiY-C3 Giy-N2 Gly-N3 Giy-N2 Gly-N3 I II I I I I I

I

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys

G

Sub-library: 1 2 3 4 6 9 1 11 12 SUBSTITUE SHEET (RULE 26) WO 97/09344 PCTIL96/00 091 SOMATOSTATIN

ANALOGS:

Biological screening of somatostatin libraries: The peptide libraries and sub-libraries were tested for their potency in inhibition of the binding of 1 25 I-Tyrll-SRIF (based on the method described by Raynor et. al. 1993 Molecular Pharmacology 43, 838-844) to membrane preparations expressing the somatostatin receptors (SSTR-1,2,3, 4 or The receptor preparations used for these tests were either from the cloned receptors selectively expressed in Chinese Hamster Ovary (CHO) cells or from cell lines naturally expressing the SSTRs. In order to validate positive signals of the binding tests, and to eliminate non-specific signals, 15 library samples of BPI-peptides that were synthesized and handled in the same procedures and assume to contain the same contaminants, were tested in the same assays as negative control samples. These samples had no binding activity in any of the assays.

The libraries are further tested in-vitro for their influence on cyclic adenosine monophosphate (cAMP) levels, tyrosine phosphatase activity, growth hormone secretion and cell growth.

The libraries are further tested in-vivo, for the 25 inhibition of growth-hormone release, amylase, gastric acid, insulin and glucagon secretion in animals.

The estimated IC,, are calculated based on the concentration of total peptides in each sub-library mixture.

However, each sub-library is composed of different peptides that may have different activity. The activity of the best peptide in any given sub-library might therefore be higher lower IC,, value), to the extent of the given value divided by the number of peptides per sub-library. In addition, the activity values of purified individual peptides might be better due to existence of salts and impurities in the total weight of the sub-library used for calculation of the concentration.

-59 WO 97/09344 PCT/IL96/00091 Solid-Dhase Somatostatin assays: Production and screening of peptide libraries attached to a solid-phase support have many advantages and may enhance the effort of finding the active.molecule.

One type of bead-binding-assay was developed with a known active somatostatin analog anchored to beads. The peptide BIM-23052 (a known somatostatin analog with the sequence:

NH

2 -DPhe-Phe-Phe-DTrp-Lys-Thr-Phe-Thr-NH) was synthesized on TentaGel-NH2 beads (these beads does not allow cleavage of the peptides), by peptide synthesizer (Applied biosystems 433A), using the recommended procedure. The sidechain protecting groups were removed by treatment with TFA and scavengers and the beads were washed and dried. Several 15 approaches are used to screen the libraries: 1. Peptides that bind the somatostatin receptors can also bind to antibodies against SRIF-14 (the native

SST

peptide), as was shown in a work which utilized monoclonal antibodies to screen phage peptide libraries (Bio/Technology 20 13;165-169, 1995) and to select active analogs. Monoclonal and polyclonal antibodies against SRIF-14 were incubated with beads carrying the BIM-23052 peptide (after blocking nonspecific sites with 1% BSA in PBS containing 0.05% Tween and 0.05% NaN3). After washes with PBS-T (PBS containing 0.05% Tween-20), each of the resin portions (reacted with either the poly- or the mono-clonal antibodies), were divided into two parts and incubated with alkaline-phosphatase conjugated to anti-rabbit or anti-mouse IgG (diluted in blocking buffer). Each incubation was for 30-45 minutes at RT. After additional washes, a substrate solution (BCIP or BCIP/NBT) was added to each of the portions. The results indicated specific staining (blue or purple color) of the beads reacted with the appropriate antibodies (polyclonal followed by anti-rabbit antibodies and monoclonal followed by anti-mouse antibodies), and no staining when the non fitting antibody combination (polyclonal followed by anti-mouse antibodies or monoclonal followed by anti-rabbit antibodies), 60 WO 97/09344 PCT/IL96/0009 1 was added. In a similar approach, anti-idiotypic antibodies against the somatostatin receptor/s are used for direct screening of the positive and negative beads and of beadsupported libraries.

2. Affinity selection. Cell membrane preparations selectively containing somatostatin receptors are incubated with bead-supported peptides (after blocking as above), after washes, the membrane-receptors are eluted from the beads and the eluted material is quantified by reacting with '12 5

-SRIF

as done in the above binding assay.

3. Soluble samples of peptide libraries are tested for there ability to inhibit the binding of biotinylated-SRIF to polyclonal antibodies against SRIF, absorbed to microtiter plate wells. Briefly, microtiter plate wells are coated with 15 5 ug/ml solution of antibodies, after 16 hours incubation at S. RT., the wells are blocked (blocking and wash solutions as in method 1) for 1 hour at RT. N-terminal biotinylated-SRIF is added to the wells at a concentration of 10-6 M together with library samples in different concentrations, in blocking 20 buffer. After 1-2 hours incubation at RT, the wells are ashed several times and an Avidin-alkaline phosphatase solution is added to the wells for 30 minutes incubation.

After additional washes, the signal is developed using the SPNPP substrate yielding a soluble product that its optical density can be recorded at 405 nm. The assay may be performed with any somatostatin analog that can be biotinylated without loss of binding activity and that antibodies that inhibit its binding to the receptors are available.

4. Soluble samples of peptide libraries are tested for their ability to inhibit the binding of antibodies against SRIF to peptides linked to solid-phase support (micro wells, beads, MultiPin crowns, cellulose filter The SRIF peptides are directly synthesized on the solid-phase support or chemically linked to the solid support after synthesis.

After blocking (solutions as in method the segmented support is incubated with an antibody solution together with -61 I WO 97/09344 PCT/IL96/00091 library samples in different concentrations in blocking buffer. After washes, a second antibody-alkaline phosphatase solution is added and after incubation and washes the signal is developed using the PNPP substrate yielding a soluble product that its optical density can be recorded at 405 nm.

The assay may be performed with any somatostatin analog that can be biotinylated without loss of binding activity and for which antibodies that inhibit its binding to the receptors are available.

Table III summarizes some of the libraries of somatostatin that were synthesized and characterized. The composition of the libraries was based on a few known somatostatin analogs. Position numbers of amino acids in the somatostatin sequence are based on the native somatostatin peptide (SRIF-14, Raynor et. al. ibid).

2 62 WO 97/09344 PCTIL96/00091 Table 111. The composition of several Somatostatin libraries.

Library Library Name Type VH-SSTI backbonecyclic 9! .1

IG-SSTI

pre-cyclic linear backbone.

cyclic pre-cyclic linear backbonecyclic DPhe Pro Val Leu Gly Meh Pro Val [Au Gly DPhe Pro Val Lcu Gly DPhc Phe DTrp Trp Meh Phe DTrp Trp M~e Plic DTrp Trp M~e I 6 Gly

-C

Gly-C2 i -Phe 7 Phe Sequence per position 8- Gly Phe DTrp Leu DTrp Leu DTrp Leu DTrp Phe Leu DTrp Phe [Au DTrp Phe Lys Pro Lys Pro Lys Pro Lys Gly Val Gly Val Gly- N2 Gly- N2 Gly-C2 Phe -l-2 h Gly-C Phe Gly-N2 Val Lys Gly G~l2V al

YS-SSTI

PV-C2lcD~h.

K

Gly-CI Gly-C2 Gly-N2 Gly-N3 Gly-C I Gly-C2 Gly-N2 Gly-N3 Gly-N3 LeuDr Ls h Phe DTrp Lys Thr Gly-N42 Phe Ala Lcu Phe Ala [Au Phe Ala Leu Gly-N2 Gly-N3 Gly-CI Gly-C2 Gly-N2 Gly-N3 Gly-CI Giy-C2 Gly-C2 Phe-C2 Phe-C2 Val Val Val Val Thr Thr Thr 2Nal DZ2Naj Thr MNal D2Nal Thr ThIr YS-SST2 backbone.

cyclic DPhe pre.ccic D1 ii Gly-N3 Phe Tyr pClPhe pNO2Phe Phe Tyr pClPhe pNO2Phe Phe Phe YS-SST3 DTrp Lys DTrp Lye DTrp, Lye DTrp Lys bcbn. DPhc cyclic Gly Pre-cyclic M~e Gly Thr Ser Val Abu Thr Ser Val Abu Thir Ser Gly Thr Ser Gly Phe-N2 Phe-N3 Phe-N2 Phe-N3 63 WO 97/09344 -PCTfIL96/ooo9I YS-SST4-A backbone- Phe-C2 DVal DMys Trp DTyr Gly-N2 Phe cyclic DAta DOm Thj Gly.N3 DLeu YS-SST4-B backbone- Thr Phe-C2 DVaI DMys Trp DTyr Gly-N2 Phe Cyclic DAla Dom Thi Gly-N3 YS-SSTS backbone- D2Nal Gly-CI Tyr DTrp Lys Val Gly-N2 Thr cyclic 2Nal Gly-C2 DVal Gly.N3 DINat Gly-N2 Gly-C I INal Gly-N3 Gly-C2 pre-cyclic WNaW Gly-Cl Tyr DTrp Lys Val Gly-N2 Th r 2Nal Gly-C2DaI GyN DINal Gly-N2 Gly-C I Nai Gly-N3 Gly-C2 VJISST-6 backbone- Phe-C I Phe DTrp Lys Gly- Phe *cyclic Phe-C2 pNO2Phe DThi Orn N2 All peptides have an amide C-terminal Example 15: BEAD-BIDN SA O VH-SST2 AND IG-SST1

LIBRARIES

Beads from each of the backbone-cyclic, the pre-cyclic and the linear sub-library samples were tested for binding of rabbit polyclonal against SRIF-l4. The bead attached

BIM-

23052 peptide served as a positive control sample since it was found to be specifically recognized by poly- and monoclonal antibodies against SRIF-14. The sub-library peptidebeads were washed, blocked and incubated with the first (polyclonal anti SRIF-14), and second (goat anti rabbit coupled to alkaline Phosphatase), antibodies. Color development was performed using the BCIP substrate yielding insoluble blue precipitation on positive beads. The resulted blue staining of the sub-libraries are summarized in Table

V.'

-64- WO 97/09344 PCTIL96/0009I Table V. staining of VH-SSTl and IG-SST1 libraries with antibodies against SRIF-14 ISub-library I Staining' Sub-librarv 11 VH-SSTl-A VH-SST1-E

VH-SSTI-C

VH-SSTI-D

Cyclic Pre-cyclic Linear Cyclic Pre-cyclic Linear Cyclic Pre-cyclic Linear Cyclic Pre-cyclic 0 4 0 2 4 2 0 2 2 0 2 IG-SSTI -A IG-SSTl-B

IG-SSTI-C

IG-SSTI

-D

Cyclic Pre-cyclic Linear Cyclic Pre-cyclic LinearE Cyclic Pre-cyclic Linear Pcyclic Staining] 2 0 3 2 0 0 3 Linear I Linear 0 VH-SST1-E Cyclic 0 3 BIM-23052 Linear 2 2 1 Staining score is given as an~ arbitrary nmereween relative to the percentage of stained beads in each group and the average density of staining.

Example 16: Y-;SSTlLIBRARY This library was designed in order to optimize the bridge size and type between positions 6 and 10 or positions 6 and 11. The library include constant amino acids at poiions 5,7,8,9,12, and different building units in position 6, 10 and 11. Each of the 4 sub-libraries contains 4 3peptides differ in their bridge type as described in table

VI.

65 WO 97/09344 Table VI. Sub-libraries of YS-SST1 library I Sub-library 1Position 11j Position i1 Posit PCTIIL96/00691 ion 6 A 1-2 A 3-4 B 1-2 B 3-4 GIy-N2 Gly-N3 Gly-Ci.

Gly-C2 Phe Phe Thr Thr Gly-N2 Gly-N3 Gly-Cl Gly-C2 Gly-CI GlY-C2 Gly-N2 Gly-N3_ Gly-Ci GlY-C2 G ly-N2 G ly-N3 :i 6 Bridge Positions: 6-11 6-11 6-10 6-10 a a.

a.

a a ja a' a 9.

a The library synthesis is illustrated in the following scheme. The cyclic sublibraries were tested for their inhibition of SRIF-14 binding to the cloned somatostatin ireceptors. The results are given in the scheme for each of the sublibrarires.

66 4 WO 97/09344 YB-SST1-LIBRARY PCT/IL96/00091 Resin Position 12 Thr 11 Gly-N2 4 G __dy.N Gly-Ci Gly-C2 Phe a *aa.

a. a a Thr

Y

LYS

DTrp

Y

Phe 14 0r Thr Ly s

Y

DTrp

Y

Pho 4

LYS

DTrp

Y

Phe 14 k Lys

Y

DTrp

Y

Phe A, k I

A

Gly-N2 Gly-N3 Gly-Ci Gly-C2 6 Gly.CI Cly-C2 GlY-N2 GIY-N3 Gly-Ci -4 kr GlY-C2 Gly-N2 .4 Gly-N3 DPhe -4 k DPhe DPhe -4 DPhe a. p a.

P a Sub-library. A 1.2 A 3-4 B 1-2 B 3-4 3200 80 2080 hSSTR4 600 5000 600So 5000 m SSTR13 >2000 -50 2o >2000 rnSTR OD2000 36 >5000 >5000" hSSTRi 380 ICSO(nM) tor activity of tow peptides per group containing 4 peptides 67 WO 97/09344 PCT/IL96/0009 1 Synthesis yields of this library were: 3.5 mg (average) for backbone-cyclic peptides and 3.2 for pre-cyclic peptides.

The linear "library" in this case contains only two analogs DPhe-Gly-Phe-DTrp-Lys-Thr-Gly-Thr-NH2 and DPhe-Gly-Phe-DTrp- Lys-Gly-Phe-Thr-NH2, That were synthesized separately.

The sub-libraries were tested for inhibition of 1251- Tyr11-SRIF to membrane preparations expressing the rat somatostatin receptor 5. The results are summarized in table

VII.

Table VII. Inhibition of 2 I-Tyr'-SRIF binding to selectively expressed rat somatostatin receptor -Inhibition of 1 2 5I-Tyr -SRIF binding Sub-library Backbone-cyclic Pre-cyclic 6 M 10- 7 M 10"iM 10-6M 10-7M 1-2 64 18 0 38 5 0 A 3-4 ND ND ND 55 14 7 B 1-2 ND ND ND 54 15 0 20 B 3-4 38 5 0 68 24 6 ND not determined Example 17: YS-SST2 LIBRARY 25 This library was designed to contain a constant bridge between two building units at positions 6 and 11, constant amino acids at positions 5, 8, and 9, and diversity in positions 7, 10, and 12. The library contains 4 sublibraries, differing between themselves in the amino acid at position 7. The inhibition of SRIF-14 binding to the cloned SSTRs by the sublibraries was tested and the results are summarized in the bottom of the synthesis scheme below: 68

U

WO 97109344 PCT1IL96/rjOOD] 0 0e@Oge 0

S

S.

0 0@ 0 OS

SO

S@

SSOS

0 6*SS FS 7r FV7al Abu D-Tr *5 S 0S 0@

S

7 F h Tyr 6 Glyy-N3 A

B

100 120 hSSTR4 3600 3600 mSSTR3 >3000 >5000 rnSSTR2 >5000 >3000 hSSTRJ 25 1000

D

1800 3000 >3000 1200 300 IC~o (nM) for activity of total peptides per group containing 12 peptides 69 'SUBSTrrU1TF.(W im rii g:o WO 97/09344 PCT/IL96/000 9 1 As shown, sublibraries C and D exhibit apparent high affinity and selectivity to the art SSTR5. Sublibrary C exhibit also high affinity to the human SSTR5 (about 100 nM).

Example 18: YS-SST3

LIBRARY

In this library Phe-building units were incorporated at positions 11 and 6 (Phe-N2 and Phe-N3 in position 6 and Phe- C2 in position 11). In the positions after these units, different amino acids were coupled using 3 molar excess of amino acid, 3 molar excess of HATU and 6 molar excess of DIEA, for duration of 2-16 hours, yielding two sub-libraries each contains 6 analogs.

The synthesis is illustrated in the following scheme: 15

A..

:i *ooo*o 70 a WO 97/09344 PCT/1L96/00091 YS-Slibar Position 12

K.-

I

Ser G13 DTrp 7 6 SUb-library: Phe-N2 /PePhe-N3 DPhe Gly DPhe

GI

wB 71 WO 97109344 PCT/IL96/00091 Example 129: YS-SST5

LIBRARY

This library was designed for optimization Of bridge size and direction between Positions 6 and 11 with simultaneous determination of the influence of various Naphtylalanine residues at position 5. The library consist of 4 sub-libraries with 16 peptides in each. The backbone-cyclic and the pre-cy -lic libraries were synthesized simultaneously.

The following scheme describes the synthesis of the library.

*25 72 WO 97/09344 PCTIIL96/00091

LIBRARY

Position 12 Thr Gly-C2 Gly-N2

GI,

11 Gly-CI Val D.VaI 9

LY

8 DTrp 7 Tyr 6 Gly-N2 Gly-N3 Val M~al

LYS

D.Trp Tyr Gly-C1 Gly-C2 INal D1NaI 2Nai W2NW 73 WO 97/09344 PCT/IL96/00091 Example 20: VH-SST7

LIBRARY

This library contains 290304 backbone-cyclic peptides in sub-libraries. The peptides were synthesized on noncleavable resin (TentaGel-NH2), yielding bead-attached peptides for screening in solid-phase-assays. The composition of this library described in table

VIII.

Table VIII. Composition of VH-SST7 library.

Position 5 7 10 i1 12 s A B rE F G

H

1 DPhe GT -N2 Lyr Ply-e Th 2Phg Gly-N D-Trp Arg Val Gl-C2 Ser 3 1Nal Phe-N2 Phg Ser Gly-C3 Val SD1NIal Ph2-N3 pcPhe Abu Phe-C-a A b u Phe-Cl Nal 2Nal Ala-N2 pFPhe Phe-C2 DNal Phe-2 Dal D2al Ala-N3 N Phe Phe-C3 2Nal Groups 12 6 6 2 2 i 7 -25 9 spC1Phe e12 -e n- Groups 14-1-- I Total-- Pept op 24192 12096 12096 145152 145152 72576 12096 41472 290304 .y "25 A, The sub-library are named for their defined position: A', An, Bn, Hn. H For each group, positions other then the defined one, contain mixtures of amina acids. In each coupling step, each non-defined position gets a mixture of amino acids (total 1 molar equivalent.of amino acids in each step in order to force the completion of each amino acid coupling and to eliminate kinetic effects, yielding non-equal presentation of peptides), that will be presented at this position.

Identification of the most active sub-library in each of the A to H group, by solid-phase assay, will lead to the 74 WO 97 0 9344 PCT/IL96/00091 composition of most active backbone-cyclic peptide from the 290304 peptides presented in the library.

The rationale for eneration and screening of new somatostatin libraries: There are currently several known Somatostatin analogs in clinical use or in clinical trials. These include octapeptide analogs based on sequence 5-12 of the native peptide SRIF-14: Octreotide, RC-160, and Somatuline (Hofland et al., Biochemical Pharmacoloqy, 50:287-297, 1995). These octapeptide analogs have been found to possess high affinity to SSTR2 and SSTR5. Another somatostatin analog, CGP 23996, which is based on sequence 3-13 of SRIF-14, binds selectively to SSTR1 and not to SSTR2. In addition, a diverse random 15 octapeptide library has been disclosed (Wright et al., Bio/Technoloqy, 13:165-169, 1995). This library revealed active peptides containing the Phe-Trp-Lys-Thr consensus equence (positions 7-10 in SRIF-14) with additional Arg and Trp residues.

Libraries were synthesized according to the present invention, based on the expectation that the selectivity of binding of the somatostatin analogs to the different somatostatin receptor subtypes could be achieved by varying the SRIF-14 fragment that is chosen for backbone cyclization.

.i WO 97/09344 PCTJJL96/00091' 2 6 7 9 10 12 12 13 14 SRI? Ala Gly I Cys Lys Asn Phe Phe Tr Ly's Thr Phe Th- Sr rs 14 Cap Cf Lys Asn Phe Phe Ti-p Lys Th-r Th- Sr S 23996 Ty -h Ser-i -1 YS6A Ala (fly (EU Lys Ann Phe EU] DTrp Lys NH' f2Nal Arg DAsn YS6B Ala (BtJ Gly Lys Ann EU] Phe flTzp Lys RH, D2Na1 __Arg DAsn td e Cys Phe frp Lys Thr Cys Thr (01) 210 RCDPhe Cys Ty ~pLys Val Ci's Ti-p uH, Somatu- 2aj, yEyDrLsVl line D2a y y ~pLeVlCys Th- NH, p W~gtCys Arg Phe TpLys Th TpCy Table III summarizes libraries that were cyclized via the backbone between Positions 6 and 11 of the SRIF-14sequence. These are constructed based on considerations of ~.analogy to the known active octapeptide sequences listed above, and are designed to leave the consensus sequence intact, by accomplishing the cyclization outside the frame of residues 7 through Novel sequences were now also selected for cyclization via the backbone, and libraries were prepared from thes 9 .4 25 sequences as described in the following Examples. These 9 novel sequences are backbone cyclized between residues 2 and 6-or between residues 3 and 7 of the SRIF-14 sequence. This marks a departure from the assumption in the background art of the necessity of the consensus sequence Phe-Trp-Lys-Thr.

3Unexpectedly, these novel libraries have revealed biological 3activity, and receptor selectivity. These finding support the conclusion that the cyclization via the backbone can yield selective biologically active conformers, arnd the utility of the libraries in designing and preparing such conformers.

76 WO 97/09344 PCT/IL96/00091 Example 21 The table below represents the diversity generated from the basis of 16 backbone-cyclic somatostatin analogs (defined by positions 5, 7, 10 and 12, with two amino acids per position), and different bridges (defined by the building units at positions 6 and 11). The two versions (A and B) differ in the direction of the amide bond of the bridge.

A.

6 7 8 9 10 11 12 DPhe Gly-Cl Phe DTrp Lys Thr Gly-N2 Thr -Des Gly-C2 Tyr Val Gly-N3 Val Gly-C3 Phe-N2 Phe-C1 Phe-N3 Phe-C2 Phe-C3 25 Some of these somatostatin analogs exhibited high affinity to the human SSTR5 (when tested for inhibition of SRIF-14 binding to the cloned SSTRs). Deconvolution revealed that the following analogs showed unexpected selectivity to the human SSTR5 as described in the following table: Estimated ICs, values (nM) for Inhibition of 5 I-SRIF-14 binding to cloned SSTRs by selected backbone-cyclized analogs are summarized in the following table.

77 WO 97/09344 PTI9/09 PR Structure SSTR1 SSTR2 SSTR3 SSTR4 hSTSrSR 3040 PheN2-Phe-DTrp. 100 >2000 >1000 1000 >1000 100 f Lys-Thr-PheC3 Val 3046 PheN2-Tyr-Trp. >3000 1000 >1000 >1000 70 100 Lys-a1~he C3T Lys-Val-PheC3-ThrI 3078 PheCl-Tyr-DTrp. 10 >2000 2000 200 Lys-Val-PheN2Thr 10 3 9 PhC-Tyr-DTrp. >3000 >0010 Lys -Val-pheNThr *Al -analogs have an amide C-terminal The unexpected advantages of PTR 3046 (and,toalse '.extent, of PTR 3079, 3082, 3088 and 301,over other somatostatin analogs is in its selectivity. The analog binds wihhigh affinity to the human SSTR-5 and much less toote SSTRs. Furthermore, the affinity to the rat and the human are similar for PTR 3046, thus, drug dosages given in rat models may predict the efficacy in humans.

Another backbone-cyclic peptide analog, PTR 3040, showed an interesting profile of selectivity. This analog shows relatively high affinity for receptor subtype SSTR-l, and very low affinity for the other receptor subtypes. While PTR 3040 showed high binding to the rat SSTR-5, its affinity to the cloned human receptor was significantly lower.

Example 22: Y-ST6 IBRnAny This library comprises 128 backbone-cyclized somatostatin analogs in 8 sub-libraries and 128 precyclic analogs in 8 additional sub-libraries. Two basic cyclizations were used: position 3 to position 7 and position 2 to position 6. Each sub-library differs in the bridge location, bridge type, and direction or amino acid at position 1 (Ala or D2Nal).

The backbone cyclized and precycjlic sub-libraries were tested for 'their inhibition of 125 1 -SRIF binding to mouse 78

C

i WO 97/09344 PCTIL96/00091 pituitary AtT20 cells. The results of these experiments are summarized in Table IX. Unexpectedly, there was considerable activity of these novel analogs that do not contain the consensus sequence, in terms of specific inhibition of SRIF binding.

Table IX. Structure and activity of YS-SST6 librarie- Sub- 1 2 3 4 5 6 7 8 9 lib. inhibition of 1'I-SRIF binding 10"'M Al Ala Gly Gly-C1 Lys Ann Phe Gly-N2 DTrp Lys C 42 91 103 Gly-C2 Arg DAsn Gly*N3 P 54 73 105 A2 D2Nal Gly Gly-C1 Lys Asn Phe Gly-N2 DTrp Lys C 72 57 72 Gly-C2 Arg DAsn Gly-N3 P 46 88 97 A3 Ala Gly Gly-N2 Lys Asn Phe Gly-C1 DTrp Lys C 44 60 76 Gly-N3 Arg DAsn Gly-C2 P 27 34 86 A4 D2Nal Gly Gly-N2 Lys Asn Phe Gly-Cl DTrp Lys C 51 69 96 Gly-N3 Arg DAsn Gly-C2 P 31 Bl Ala Gly-C1 Gly Lys Asn Gly-N2 Phe DTrp Lys C 10 54 77 Gly-C2 Arg DAsn Gly-N3 P 50 36 88 B2 D2Nal Gly-C1 Gly Lys Asn Gly-N2 Phe DTrp Lys C 13 52 86 Gly-C2 Arg DAsn Gly-N3 P 16 37 74 B3 Ala Gly-N2 Gly Lye Asn Gly-C1 Phe DTrP Lys C 31 66 52 Gly-N3 Arg DAsn Gly-C2 P 12 37 86 D2Nal _EIZN2 GlY Asn Gly-C1 Phe D3Tz Lys~ T I Lys Gly-N3 DAen I Glv-C2 fl~nn I Gly-C2 Example 23: IG-SST9 LIBRARY In order to more systematically test the necessity of any given frame in the SRIF sequence for biological activity of the analogs, it was decided to synthesize in parallel a library of octapeptide analogs that differ from one another in spanning different parts of the SRIF structure. Each octapeptide sub-library is shifted from the next by one residue. Thus, the first sub-library spans residues 7 to 14 of SRIF-14, the second sub-library spans residues 6 to 13 of SRIF-14, and so on. Thus, this library comprises a total of 14 overlapping backbone-cyclized octapeptides with a shift of 79 WO 97/09344 PCT/IL96/00091 one residue between sub-library. The synthesis is achieved by simultaneous synthesis of the analogs from different starting points, such that the coupling of the building units is performed for all of the sub-libraries at the same time.

In all of these sub-libraries, the backbone cyclization is accomplished between one glycine C2 unit distal to the N terminal of the peptide sequence and one glycine N3 unit proximal to the N terminal end of the peptide sequence.

Library IG-SST9 is represented in the following scheme:

I..

.5 80 WO 97109344 PCT/1L96/00091 IG-SST-9 Library 12

GI)

11 p Ser Gly~ C2 Plie Thr Phe I C2 Ijls Trp /IDTrp Gly-N3

T

Trp I Gly ir Gly Is L I C2 DTrp N3 Trp IXITrp Pjie Gly-N3 Tmp PTrp Pic P ie Gly. N: Lys Trp/ Tmp GIy C2 Pie Gly-N3 Tm I DTrp Gly C2 e ASn Hys Gly N3 1 Sublibrary: A B C

D

Estimated IC50 (nM) for cloned SSTRs hSSTR 1 1000 600 >2000 100 mSSTR2B 400 >3000 >2000 >10000 iSSTR3 250 hSSTR4 400 400 700 100 Based on total weight per group of 2 peptides Ala E

G

>3000 >5000 >2000 >2000 >10000 700 >2000 Sublibrary I'D" which contains the frame 4-11 showed the most interesting activity with high affinity to SSTR-5 and SSTR-1. This synthetic mixture was further purified by HPLC 3to remove by-products, and the more purified sample was tested again for binding to the cloned receptors. The result ICs 0 (nM) are: 81 WO 97/09344. PCT/IL96/000 9 1 GSS9Dur SSTR-1 SSTR-2 -SSTR- NDR-4 SSTR-5 I I-S9DPr 600 ND >2000 NDR- 100 Thus" the analogs Lys-Gly3-Phe.PheTrp-.Lys..GlyC 2 Phea .nd Lys-GlyN3Phe.Phe-Trp-.Lys GlyC2 -Phe-NH 2 exhibit apparent high affinity and partial selectivity to the human Examol1e 24: SSTl1

LIBRARY

Different phenylalanine building units (PheBi: Phe-N2, Phe-N3, Phe-C2, Phe-C3) are used in this library as bridging arsfor the generation of bcon-ylzdalgsof

SRIF-

14 sequence 4-11 (sub-library D in library IG-SST9). In 1addition, the non-bridging Phe residue (position 6 or 7) is substituted with various Phe and Nal derivatives: DPhe, ~pNOPhe, pClPhe, pFPhe, phenylglycine (Phg), DPhg, L2Na1, D2Na1. This provides a library of 18 groups with 16 analogs per group as described in the following representation: *4 5 6 7 8 9 10 11 Lys Asn Phe Phe Trp Lys Thr PheBi (4) :DLys PheBU PheBU DTrp (4)

PNO

2 Phe DPhe pClPhe

PNO

2 Phe pFPhe pClPhe pFPhe DPhg Phg L2Nal DPhg D2Nal L2Nal D2Nal 82 WO 97/09344 PCT/1L96/000 9 1 Example 25: YS-SST-12 This library is Composed of retro, sequences of somatostatin backbone cyclized analogs. With two different building units (Gly-N3, Gly-C2) at position 6 and two different building units (Phe-C2 ph.e-N3) at position 11.

This combination gives two bridge types that are similar in total size but different in the amide bond position and orientation. The library composition and the preliminary biological activity of the SubJlibraries are illustrated in the following scheme: 1.83 WO 97/093" WO 97O93~PCTIIL96/00091 YS-SST-12 library 2-Nal 6 GIy-N3 7 D-Phe p-NH2-Phe p-CI-D-Phe D-2-Nal Giy-C2 D-Phe p-NH2-Phe p-CI.D.Phe 0 8 D.Trp Trp 9 D.Lys D-Glu D-Thr D.

1 1 25 11 Phe-C2 Phe-C2 PI A B D.Trp Trp D-Lys D-Glu D-Thr D-VaI I I ,I Phe-N3 Phe-N3 Phe-N3 D E F S. .5 -Val ie-C2

C

Estimated ICso (nM) for cloned SSTRs (based on total weight per group of 18 peptides): hSSTRI >3000 >1000 >1000 >10000 >1500 >1500 mSSTR2B >5000 2000 >5000 >10000 >1000 >1000 mSSTR3 >10000 2000 >2000 >3000 2000 900 hSSTR4 800 150 200 2000 200 200 84 WO 971093"4 PCTIIL96/0 .0091 Examp~le 26: This library contains bridges between a Phe-C.3 building unit at position 11 and different Phe and Lys building units at position 6. The library is composed of 8 sublibraries containing 12 backbone cyclized-analogs in each, as illustrated in the following scheme.

85 WO 97/09344 PCTIL96OOO91 12 Thr Val Aa 11 Phe-C3 0

GY

L s D-Lys .*6 7 Pher 6 Phe-N2 Phe-N3 Lys-N2 Gly-N2 Phe-N2 Phe-N3 Lys-N2 Gly-N2 A B C D E F G

H

86 WO 97/09344 PCT/IL96/00 09 1 INTERLEUKIN-6 RECEPTOR PEPTIDE

LIBRARIES:

Interleukin-6 also known as interferon-beta-2, is a pleiotropic cytokine, which acts as a growth and differentiation factor for a number of cell types.

Overproduction of IL-6 has been implicated in the pathogenesis of multiple myeloma and in post-menopausal osteoporosis. Inhibition of the action of IL-6 should be of clinical benefit in the treatment of multiple myelomas, a malignancy in which the growth stimulatory effect of IL-6 contributes to tumor growth.

IL-6 is believed to interact sequentially with two transmembrane receptors, the low affinity IL-6 receptor

(IL-

6R alpha, also denoted gp80) and the signal transducer via distinct binding sites. The gpl30 protein is also 15 involved in signal transduction of a number of other growth factors or hormones (reviewed by Hirano et al., Stem Cells 12, 262-277, 1994).

It has been disclosed by Savino et al. (EMBO J. 13, 5863-5870, 1994; EMBO J. 13, 1357-1367, 1994), that site 20 directed mutagenesis of IL-6 residues that are presumed to interact with the gpl30 subunit, can yield antagonists that maintain unimpaired affinity to IL-6R alpha but no bioactivity due to inability to bind to gpl30. Mutation of residues A229 and N231 were shown to prevent IL-6 signaling.

It has been further disclosed that inhibitory peptides may be designed to prevent interaction of IL-6 and its receptor. Grube and Cochrane Biol. Chem. 269, 20791- S20797, 1994) disclose a deca-peptide spanning residues 249 through 258 of the IL-6R molecule which is active in preventing the b io activity of IL-6. This peptide, is more active then the 16- amino acids sequence Y249-T264.

According to this disclosure, the four arginine residues corresponding to positions 250, 252, 256 and 258 of the receptor sequence are essential for IL-6 inhibition. In the following depiction of the sequences involved in the inhibition of IL-6, the underlined residues are those considered as essential: 87 WO 97/09344 PCT/L96/00091 active 249 258 268

Y-R-L-R-F-E-L-R-Y-R-A-E-R-S-K-T-F-T-T-W

Inactive inactive Additional studies have shown that a peptide starting with leucine 255 of the IL-6R and extending beyond the known inhibitory peptide (249 through 258 of the IL-6R) towards the carboxy terminus, at the 3' side, is also an effective inhibitor (Revel et al., 1995), indicating that not all four arginines are necessary for the inhibitory activity of this 15 peptide sequence.

According to the present invention, libraries are designed to provide backbone cyclized peptidomimetics based on these and other novel peptide sequences to optimally inhibit IL-6 bioactivity without disrupting normal cell 20 functions, including those mediated via gpl30 activation by other growth factors or immunomodulators. Backbone cyclized :i peptidomimetics are disclosed that achieve improved metabolic stability and oral bioavailability without interfering with the residues identified as essential for inhibitory function 25 of these peptides.

Suitable targets for inhibition by peptidomimetics according to the present invention will include 1) the interface between the IL-6 molecule and IL-6R; 2) the interface between IL-6 and gpl30; 3) the interface between IL-6R and gpl30. The peptide sequences to be modified are derived either from the IL-6R molecule, or from the IL-6 molecule itself.

Libraries of backbone cyclized peptidomimetics will be screened for inhibitory activity in known test systems for IL-6 action. The most active compounds will be isolated from the pooled libraries following individual assay. The IL-6 response can be conveniently measured in terms of growth 88 WO 97 0 9344 PCT/IL96/00091 inhibition of myeloleukemic Ml cells. A well calibrated dose dependent inhibition of growth measured after 3 days of culture provides a quantitative assay of IL-6 action. Other cell types such as myelomas are growth stimulated and can also be used to quantitate the response to IL-6.

In order to optimize the activity, the length and cyclization state of the peptides is varied in order to mimic the conformation of the peptides as predicted by three dimensional computer models.

The initial libraries, are designed with the aim of identifying the best cyclization location and size within linear peptides derived from sequences 249-264 particularly 249-258 and 255-264 and peptides derived from other candidate contact positions of the IL-6R, the IL-6 and the 15 molecules.

Example 27: The first backbone-cyclic peptide library of residues 255-264 (YK-IL11), contains 11 sub-libraries differ in the 20 cyclization points as described in table X, leaving the Arg256, 258,261 unchanged and substituting the cyclization points amino acids with Gly-building units. The shortest distance between two bridgeheads is 5 amino acids.

25 Table X. Different cyclization points of YK-ILI1 library.

255-259 257-262 259-263 260-264 255-260 257-263 259-264 255-262 257-264 255-263 255-264 Each sub-library contain 12 peptide with different building units at the cyclization points as indicated in Table XI.

89 WO 97/09344 PCT/IL96/00091 Table XI. Peptides containing different bridge type and size.

C-terminal unit Gly-C1 Gly-C2 Gly-C3 Gly-N2 Gly-N3 N-terminal unit Gly-N2 N2-C1 N2-C2 N2-C3 Gly-N3 N3-C1 N3-C2 N3-C3 Gly-Cl C1-N2 C1-N3 Gly-C2 C2-N2 C2-N3 Gly-C3 C3-N2 C3-N3 Example 28: The second library is synthesized with the use of Argbuilding units as cyclization points at positions 256, 258, 15 261 and use of the original sequence (Leu255, Ala259, etc.) modified amino acids as building units additional libraries are synthesized based on the biological information obtain from screening the initial libraries, using additional types of building units and substitution of other sequence amino 20 acids.

Example 29: The initial backbone-cyclic library of the 249-258.

peptide (YK-IL(2), is composed of 7 sub-libraries, differ in the cyclization points (249-257, 249-255, 249-254, 257-253, 251-257, 251-255, 253-257), leaving the Arg250, 252,256,258 unchanged and substituting the cyclization points amino acids with 6 different Gly-building units yielding 12 peptides differ in their bridge, in each sub-library. The shortest distance between two bridgeheads is 5 amino acids.

In addition, backbone cyclic peptide libraries composed of shorter peptides of the above sequences (249-258 and 255- 264), are synthesized with systematic deletions of amino acids that are not essential for activity.

90 0 WO 97/09344 PCT/IL96/00091

I

WI

a Examp~le 30: YS-IL-6 library The library utilizes overlapping backbone cyclized decapeptides to scan the region of the IL-6 receptor that was found to have inhibitory activity. The overall sequence of 5 this region divided into 12 overlapping decapeptides is illustrated in the following table where letters represent sublibraries and numbers represent original position in the IL-6 receptor.

0A B C D E F G R 1- 1 K L 269 Met 268 Trp Trp 5267 h Thr Thr Thr.

265 Phe Phe Phe Phe Phe 264 Thr Thr Thr Thr Thr Thr 263 Lys Lys Lys Lys Lys Lys Lys 262 Ser Ser Ser Ser Ser Ser Ser Ser 261 Arg Arg Arg Arg ArgAr Ag Ar Ag 260 Glu Glu Glu Glu rGlu Glu Glu Glu Glu Glu 259 Ala Ala Ala Ala Ala Ala Ala IAla Ala Ala 258 Arg Arg Arg Arg _Arg Arg Arg Arg Arg Arg 257 Tyr Tyr Tyr Tyr Tyr Tyr Tyr Tyr Tyr I- 256 Arg Arg Arg Arg Arg Arg Arg Arg 255 Leu Leu Leu Leu Leu Leu Leu 254 Glu Glu Glu Glu Glu Glu 253 Phe Phe Phe Phe Phe 252 Arg Arg Arg Arg 251 Leu Leu Leu 250 Arg Arg 249 Tyr Each sublibrary represents one frame-shift of the IL-6 receptor sequence and contains ten analogs which differ in -91 tWsn the zcfowong stcn (f P C j S N t e r a i 2 6 7 2 2 2 91 3- 8E For sxaru:2. th-le j=rra o- sublibr;-v L,

~T

reCEPtor SeUelCe 260-269 (with teOZcrinal seu~ne in, th lef, t coluhnn desijra_t e "IIi', s ijslatsdt .bC1ow 26 Tr Githr IT 3 Gr 11,14 ThzD T 1r Trp I x 1 11,11 1 1 1- 1 Il 11 z 2 6 -T Thr 1

T

26 Th1-r TtC2Ir. l h h- h h h T h rhC- C2 Ta jh Serr Ser -r Th r Th S lj 263* LLs L 2 y v L GlC Lc/S L1,s L 262 e V lC e iC Th otham fer eleven si-b1 ibraries were synthesized u h 9 sa~eformat as showl-I ahOve, hy using the sane bildjng Unit types at the correspondin P,,,t~ons within the pr amln C acid Subsecrerce from the crizinaJ. !L-6 receptor Eeo- enc Th lib ary us~ contain 12 sublibrardies TW t h backbone CYc1ized an~g in~ each.

It is to be understood that a reference herein to a prior art document does not an admission that the document forms Part of the common general knowledge in the art in Australia or in any other country.

In the claims which follow and in the preceeding description of the invention, except where the context requires otherwise due to express language or necessary 3 implication, the word "comprising" or grammnatical variations thereof, is used in the ~-~RAs e of "including", ie the features specified may be associated with further features in v 'ous embodiements of the invention.

-o 92

Claims (12)

1. A backbone-cyclized peptide analog of a fragment of bacterial/pemeabibty increasing protein 23 (BP1 23 having- anti-fungal activity, comprising a peptide sequence of 1RP1 23 wherein at least one pair of backbone nirrogens in the peptide sequence is linked together to form a backbone-cyclized peptide analog having anti-fungal activity and having the general fornula Q_ {AAj a-N-CH(R)-CO- f{AA} NH-CH(R').CO- f{AA) ±-E Formula (1) wherein: d, e, and f each independently designates 0 or an integer from~ I to 10; each {AA} designates an amino acid residue or the residue of a plurality of amnino acids linked together through peptide bond ing; wherein each {AA) may be the same or different; Q represents H or an acyl group; E represents a hydroxyl grou~p, a carboxyl protecting group or an amino group, or the carboxy terminal group CO-E, wherein The CO) is part of can be reduced to Cli 2 -OH-jor CH{O; each of R and R! is independently hydrogen or an amino acid side-chain optionally bound with a specific protecting group; and the line designates a bridging group of the formula: or (ii) -X-Iv-Z- wherein: M and W are independently selected from the group consisting of disulfide, amide, thioether, thioester, imime, ether, and alkene; and X, Y and Z are each independently selected fronm the group consisting of aikylene, substituted alkylene, aryl ene, homo- or hetero- cycloalkylene and substituted cycloajlkylene.

2. The peptide analog of claim 1 wherein -X-M4-Y-W-Z- is: -(CH2) 1 -M- *(CH2)y-W-(Cu: 2 )...whereint M adW are as recited above; x and 2 each independently designates an Integer of from I to 10, and y is 2ero or ami integer of from I to 8, with the proviso that if y is zero, W is absent.

3. A backbonc-cyclized peptide analog of a fragment of bacteriallpermeabilii 3 increasing protein 23 (B.P1 23 having anti-fungal activity, comprising a 'RA _3 peptide sequence of B?12 3 wherein the backbone of the peptide anaglog is cyclized to a side- chain of an amaino acid to form a backbone-cyclized peptide analog with anti-fungal activity and having the general Iformula Q-{AAld-N-CEi(R)COJAAI-NC.CO.{AAI pKE 1'ormula (HI) wherein: ci, e, and f eah independently designates 0 or an integer from 1 to 10; each {AA} designates an amino acid residue or the residue offn plura lity of amino acids linkled together through peptide bondig, wherein each {AA} may be the same or different; E represents a hydiroxy] group, a car-boxyl protecting or an amnino, group, or CO-E, wherein the CO is part of {AAJ, can be reduced to CH- 2 R is an amnho acid side chain optionally bound with a specific protecting group; and the line designates a bridging group of the formula: or (ii) -X-M-Z- wherein M and W are independently selected from the group consisting of disulfide, ariide, thioether, imine, ether, and alkene; X, Y and Z are each independently selected from the group consisting of alkylene, substituted alkylene, arylene, cycloalkylene and substituted cycloalklylent!.

4. The peptide analog of claim 3 wherein is: -(CH2)X-M-(CH2)y-W-(CE2),..wherein M arid W are as recited above; x and z each :e.:independently designates an integer of from I to 10, and y is zero or an integer of from 1 to 8, with the proviso that is y is zero, W is absent. A backbone.-cyclized peptide analog of a fragment of *bacterial/permeability increasing protein 23 (BP2) having anii-fungal activity, comprising a peptide sequence of BP1 3 wherein the backbone-c yclized peptideuaalog has ani-fungal activity and has the general-formula (MI): Q-iAAd-BU -{AAha-BU 2 {AA).-B3U 3 {AA} b-BU'i- AA}f-.E Formula (111) wherein: a and b each independently designates an integer from 1 to 8 or zero, di, e, and f each independently designates an integer from I to 10 or zero; {AA) designates an amino acid residue -IfN-CU(R)-CO-wherein R is an amino acid side chain, optionally bound with a 94 specific protecting group, and the amino acid residues in each chain may be the same or different; Q represents H or an acyl group; E represents a hydroxyl group, a carboxyl protecting group or an amino group, or the carboxy terminal group CO-E, wherein the CO is part of can be reduced to CH 2 -OH or CHO; BU represents an N-O-functionalized derivative of arino acids of formula (IV): N-CH(R')-CO-- X G Formula (IV) wherein X is a spacer group selected from the group consisting of alkylene, substituted alkylene, arylene, cycloalkylene and substituted cycloalkylene; R' is an amino acid side chain, optionally bound with a specific protecting group; and G is a functional group selected from the group consisting of amines, thiols, alcohols, carboxylic acids and esters, and alkyl halides; which is incorporated into the peptide sequence and subsequently selectively cyclized via the functional group G with one of the side chains of the amino acids is said peptide sequence or with another w-functionalzed amino acid derivative; and the lines designate a bridging group of the formula: or (ii) -X-M-2- wherein; one of the lines may be absent; M and W are independently selected from the group consisting of disulfide, amide, thioether, thioester, imine, ether, and alkene; and X, Y and 2 are each independently selected from the group consisting ofalkylene, substituted alkylene, S arylene, homo-cycloalkylene, or hetero-cycloalkylene and substituted cycloalkylene.

6. A backbone-cyclized peptide analog of a fragment of bacterial/permeability increasing protein 23 (BPI 3 having anti-fungal activity comprising the following BPI23 pepride sequence: Lys-Trp-Leu-le-Gl--Leu-Phe-His-Lys-Lys wherein up to four amino acid residues of the BPI3 peptide sequence are replaced with a building unit, a different amino acid residue or is absent and wherein the BPI2 3 peptide sequence has at least one building unit with at least one backbone nitrogen in the peptide sequence linked to a side chain of at least one other amino acid in the peptide sequence or to at least one Other backbone nitrogen in the peptide sequence by a bridging grouj~c ornpnsjsing a disulfide, amnide, tbioether, thioester, imine, ether, or alkenieto font- a backhone-cyclized peptide analog having ariti-f..mgal activity.

7. The peptide peptide analog of claim 6, wherein at least two building units are incorporated in the SPT23 peptide sequence-

8. The ptptidc analog of clim 7, whei-cin noe of the building unit3 arc located at the end of the BP123 peptide sequence.

9. The peptide analog of claim 8, wherein at least one pair of backbone nitrogenm in the BP1 23 pept-ide sequence are linked together. The peptide analog of claim 8, wherein the bridging group has the formula: or (ii) -X-M-Z- wherein. M and W are independently selected from the group consisting of disulfide, amide, thioether, thioester, irnine, ether, and alkene; and X, Y and Z are each independently selected from the group consisting of alkylene, substituted alkylene, axylen-e, hoino- or hetero- ***cycloalkylene adsubstituted cycloalkyleae. The peptidle analog of claim 10 wherein is: -(CI2)-M.(CH2)yW.(Ch.2,)whereifl M and W are as recited above; x and 2 each independently designates am integer of from 1 to 10, and y is zero or an integer Of fOT-mnI to1 8, with the proviso that if y is zero, W is absent.

12. The paptide analog of claim 8, wherein at least one backbone nitrogen is **:cyclized to a side-chain of an amino acid.

13. The peptide analog of clairn 8, wherein the building Unit is an N'.-t-fiunctionaljzed derivative of amino acids of formula (rV):

96- X G Formula (IV) wherein X is a spacer group selected from the group consisting of alkylene, substituted alkylene, arylene, cycloalkylene and substituted cycloalkylene; R' is an aminmo acid side chain, optionally bound with a specific protecting'group; and G is a functional group selected from the group consisting of amines, thiols, alcohols, carboxylic acids and esters, and alkyl halides, wherein the building unit is incorporated into BPI23 peptide scquence and cyclizcd via the functional group G with one of the side chains of the amino acids in said peptide sequence or with another w-functionalized amino acid derivative. 14. A backbone-cyclized peptide analog of a fragment of bacrerial/permeability increasing protein 23 comprising a peptide sequence having at least one building unit having an Nt-derivative of an amino acid, wherein at least one backbone nitrogen in the peptide sequence is linked to a side chain of at least one other amino acid in the peptide sequence or to at least one other backbone nitrogen in the peptide sequence by a bridging group comprising a disulfide, amide, thioether, thioester, imine, ether, or alkene to fonrm a backbone-cyclized peptide analog, wherein the peptide sequence has the fonuJa: Q-Lys-AA2-AA3--AA4-A-AAe-AA7--AAr-AA Lys-E wherein: Q represents H or an acyl group; E represents a hydroxyl group, a carboxyl protecting 9 group or an amino group, or the carboxy terminal group CO-E, wherein the CO is part of an amino acid residue, can be reduced to CH 2 -OH or CHO; AA 2 is Trp, 2Nal, D2Na, INal, ~..:DINal, Gly-C*, or Gly-N*; AA3 is Leu, Gly-C* or Cly-N"; AA, is absent, Ile, Gly, Ala, Gly- C1 or Gly-N*; AA 5 is Gi, Gly-C* or Gly-N*; AA6 is Leu, Gly-C* or Gly-N*; AA 7 is Phe, DPhe, Phg, pNO2Phe, pFPhe, Gly-C' or Gly-N*; AAs is His, Gly-C* or Gly-N*; AA 9 is Lys, Gly-C* or Gly-N; and is an integer from 1 to 3, wherein a bridging group extends from one of AA 2 AA 3 AA 4 or AA TO one of AA, AA7, AA8, or AA to form a cyclic structure. The backbone-cyclized peptide analog of claim 14, wherein AA 2 is Trp or Gly-C2; AA 3 is Leu or GIy-C2; AA, is Ile or Gly-C2; AA is Gin or Gly-C2; AA 6 is Leu or Gly-N2; AA 7 is Phe or Gly-N2; AAs is His or Gly-N2; and AA 9 is Lys or Gly-N2. -97 16. The backbone-cyclized peptide analog of claim 15, wherein AA 2 is Gly-C2; AA3 is Leu; AA 4 is Ile; and AAs is Gin. 17. The backbone-cyclized peptide analog of claim 15, wherein AA 2 is Gly-C2; AA 3 is Leu; A 4 is let; and AA is Gin; AA 6 is Leu; AA 7 is Phe; AAs is Oly-N2; and AAg is Lys. 18. The backbone-cyclized peptide analog of claim 14, wherein AA 1 is Lys; AA 2 is Trp; AA3 is Len; AA 4 is Ile, Gly or Ala; AA 5 is Gly-C2; AA 6 is Leu; AA 7 is Phe, DPhe, Phg, pNO2Phe, or pFPhe; AAs is His; and AA is Gly-N2. 19. The backbone-cyclized peptide analog of claim 14, wherein AA, is Lys; AA 2 is 2Nal, D2Nal, INal, or DINal; AA 3 is Gly-C1, Gly-C2, Gly-N2 or Gly-N3; AA 4 is Ile; AA 5 is Gn; AAs is Leu; AA 7 is Phe; AAg is Gly-CI, Gly-C2, Gly-N2 or Gly-N3; and AA is Lys, wherein if AA3 is Gly-C1 or Gly-C2, AA 8 is Gly-N2 or Gly-N3, and ifAA 3 is Gly-N2 or Gly-N3, AAs is Gly-Ci or Gly-C2. 20. The backbone-cyclized peptide analog of claim 19, wherein AA2 is INal. 21. A method for the preparation of a backbone-cyclized peptide analog of a fragment of bacteriallpermeability increasing protein 23 (BP1 2 3 having anti-fungal activity, comprising a peptide sequence of 1PI23 having at least one building unit comprising an W- derivative of an amino acid, wherein at least one backbone nitrogen in the peptide sequence is linked to a side chain of at least one other amino acid in the peptide sequence or to at least one other backbone nitrogen in the peptide sequence by a bridging group comprising a disulfide, amide, thioether, thioester, imine, ether, or alkene bridge to formn a backbone- cyclized peptide analog; saidinmethod comprising the steps of: providing a BPb3 peptide sequence; and incorporating into the peptide sequence at least one N-w-fuctionalized derivative of an amino acid of formula (IV): V* 0 9e 0 0. (.000 .0 *SS0 0000* 0 -98 I I Formula (lIV) whereizi X is a spacer group selected from the group consisting of alkylene, substt.ued alkylene, arylene, cycloaflcylene and subsTituted cycloalkyi-ene; R' is an amino acid side chain optionally bound wvith a specific protecting group' and G is a functional group selected from the group consisting of araines, thiols, alcohols, carboxcylic acids and esters, aldehydes, alcohols, and alkyl halides, by selectively cyclizing a functional group G with another w- functionalized amino acid derivative or with one of the side chains of the amino acids in said peptide sequence to form the backbone-cyclized BP1 23 pepride analog. 22. The method of claim 21 wherein G is an amine, thiol or carboxyl group. 23. The method of claim 21 wherein R is CE 3 (CE-3) 2 CH-, -(C$H 3 2 CIi.CH 2 CE3CH 2 -CH..(C1 3 CHi 3 S(CH2)2-, HOCH 2 CH 3 CH(01iy E S-071 2 NH(CH 4 C(N2)2NH(C 2 3 H0l-phenylICH 2 benzyl, mehlnoe or rnethylimidazole. *24. The method of claim 21 for the preparation of a backbone- cyclized peptide analog of a, fragment Of bacTeria/permeability increasing protein 23 (BP1 23 9*9*..having anti-fungal activit y, wherein the backhone-cyclized peptide analog has the general formula Q- Cli(R)-CO.. JAA} -NH-CHi(R) C-C. {AAJ f-E Formula (I) 99 wherein: d, e, and f each independently designates 0 or an integer frocm I to 10; each {AA) designates an amino acid residue or the residue of a plurality of ardino acids linked Together through peptide bonding, wherein each (AA) may be the same or different; Q represents H or an acyl group; .E represents a hydroxyl. group, a carboxyl protecting group or an amino group, or the carboxy terminal group CO-F, wherein the CO is part of can be reduce .d to C11 2 -Oli or CHO; each of R and R! is independently hydrogen Or an amnino acid side-chain optionally bound with a specific protecting group; and the line designates a bridging group of the formnula: or (ii) -X-M-Z- wherein M and W are independently selected from the group consisting of disulfide, amnide thioether, iinine, ether, and alkene; X, Y, and Z are each independently selected from the group consisting of alkylene. substituted alkylene, arylene, cycloalkylene and substituted cycloalkylene;- wherein at least one N-w -functionalized derivative of an amino acid of formula (TV): N-CR(Rh)-C0O x I *I Formula (NV) is incorporated into the peptide sequence, wherein X is a spacer group selected fromu the :grouip consisting of alkylene, substituted alkylene, arylene, cycloalkyleae 'and substituted cycloalkylene; R' is the side chain of an amino acid, optionally bound with a specific protecting group; and Gi is a functional group selected from the group consisting of arnines, *:thiols, alcohols, carboxylic acids and esters or alkyl halides, by selectively cyclizing The functional group G with another co-functionalized amino acid derivative to form the backbone-cyclized BPhi peptide analog. The method of claim 21 for the preparation of a backbone-cyclized peptide analog of a fragment of bar-teriallpermeability increasing protein 23 (1BPf2 3 having anti-fungal activity, wherein The baclcbone-cyclized peptidle analog has The general Formula 100 Q- {AA}d-N-CH(R)-CO- {AA.}-NH-CH-CO- {AA}r-E Formula (II) wherein: d, e, and f each independently designates 0 or an integer from 1 to 10; each {AA} designates an amino acid residue or the residue of a plurality of amino acids linked together through peptide bonding, wherein each {AA} may be the same or different; E represents a hydroxyl group, a carboxyl protecting or an group, or CO-E, wherein the CO is part of {AA), can be reduced to CH 2 -OH; R is an amino acid side chain optionally bound with a specific protecting group; and the line designates a bridging groutp of the formula: or (ii) wherein M and W are independently selected from the group consisting of disulfide, amide thioether, imine, ether, and alkene; X, Y, and Z are each independently selected from the group consisting of alkylene, substituted alkylene, arylene, cycloalkylene and substituted cycloalkylene; wherein at least one N-w -functionalized derivative of an amino acid of formula (IV): N-CH(R')-CO- 9 x Formula (IV) is incorporated into the peptide sequence, wherein X is a spacer group selected from the group consisting of alkylene, substituted alkylene, arylene, cycloalkylene and substituted cycloalkylene; R' is the side chain of an amino acid; and G is a functional group selected from the group consisting of amines, thiols, alcohols, carboxylic acids and esters or alkyl halides, by selectively cyclizing the functional group G with one of the side chains of the amino acids in said peptide sequence to form a backbone-cyclized BPI2 3 peptide analog C The method of claim 21 for the preparation of a backbone-cyclized bicyclic peptide analog of a fragment of bacterial/permeability increasing protein 23 (BPln) having anti-fungal activity, wherein the backbone-cyclized bicyclic peptide analog has the general Formula (ll): 101 Q-{AA}-BU -{AA}-BU2 {AA},-BU 3 -BU 4 -E Formula (I) wherein a and b each independently designates an integer from 1 to 8 or zero; d, e, and f each independently designates an integer from 1 to 10 or zero; {AAJ designates an amino acid residue -HN-CH(R)-CO. wherein R is an amino acid side chain, optionally bound with a specific protecting group, and the amino acid residues in each chain may be the same or different; Q represents H or an acyl group; and the lines designate a bridging group of the Formula: or (ii) wherein one line may be absent; M and W are independently selected from the group consisting of disulfide, amide, thioether, thioester, imine, ether, and alkene; and X, Y and Z are each independently selected from the group consisting ofalkylene, substituted alkylene, arylene, homo- or hetero-cycloalkylene and substituted cycloalkylene; and each BU represents an N-w-functionalized derivative of an amino acid of the formula (IV): -N-CH(R')-CO X *.G Formula (IV) wherein X is a spacer group selected from the group consisting of alkylene, substituted i alkylene, arylene, cycloalkylene and substituted cycloalkylene; R' is an amino acid side chain, optionally bound with a specific protecting group and G is a functional group selected from the group consisting of amines, thiols, alcohols, carboxylic acids and esters, aldehydes, *alcohols, and alkyl halides, by selectively cyclizing a functional group G with another o- functionalized amino acid drivative or with one of the side chains of the amino acids in the peptide sequence to form backbone-cyclized peptide analogs and further cyclizing a second functional group G with yet another w-functionalized amino acid derivative or with one of the side chains of the amino acids in said peptide sequence to form a backbone-cyclized bicyclic BPI23 peptide analog. -102- 103 27. The m~ethodt of claiM 21 which fbrthtr comprises providing a supported peptide axialoo by covalently coupling the analog to an insoluble polym eric support. 28. The method of clam 21 for the preparaiion of a backbone-cyclized peptide analog of a fragpint of bacte-riajpermneability increasing protein 23 (BPJl3) having anti-fungal activitY, wherein i-he peptide sequence has the formula: wherein up to four am-ino acid -residues of the BP 23 peptid: sequence are replaced with a building unit, a different amino acid residue or is absent and wherein the RP1 23 peptide sequence has at least one building unit with at least one backbone nitrogen4 in the peptide sequence linked to a side chain of at least one other amino acid in the peptide sequence or To ait least one other backbone nitrogen in the pepTide sequence by a bridging group Comprising a disalfide, amride, thioether, th-ioesjer, irnine, ether, or alkene to form~ a backbone-cyc lized peptide analog having anti-funigal activity.

213. The method of claimn 21 for the preparation of a backcboze-cyclized peptide analog of a fragment of bacteria]~pei-meability increasing protein 23 (BP1 23 having anti-ftingal activity, wherein the peptide seq uence has the formula. wherein., Q represents H or an acyl group; E represents a hydroxyl group, a carboxyl protecting group or an amino group, or the carboxy tertninal group MOE, wherein the CO is pant of an ~nnno acid residue, can be reduced to Clh1rOH Or CHO; AA 2 is Tip, 2Nal, D2Nal, INal, DNal, Gly-C*, or Gly-N AA 3 is Leu, Gly-C* or Gly-N*; AA4 is absent, Ie, Gly, Ala, Gly-C* or Gly-N*'; AA 5 is G4n Gly-C4 or Gly-N'*- AA 6 is Leu, Gly-C* or Gly-N*; AA 7 is Phe, D)Phe, Phig, pNO2?he, pFPhe, Gly-C* or Gly-N AAS is His, Gly-CP or Gly-N*; AA9 is Lys, Gly-C* or Gly-N,,; and #is an integer from I to 3, wherein a btidging group extends frOnM one of AA2, AA 3 AAj, Or AAk to one of AA6, AA 7 A-As, or AA9 to formn a cyclic Dated this 26 day of August 2002 Peptor Ltd SRA Yissum Research Development Company of the Hebrew University of Jerusalem by their attorneys /VT O~Freeh ills Carter Smith Beadle